GENERAL INFORMATION FOR THE 2016 CANADIAN DIGESTIVE DISEASES WEEK™ (CDDW™)

SCIENTIFIC SESSIONS:
The Gastroenterology Residents in Training (GRIT) Program (by invitation only) will be held at the Fairmont Queen Elizabeth.

Registration Desk Hours – Foyer, Conference Level
Tuesday, February 23 12h00-21h30
Wednesday, February 24 08h00-20h30
Thursday, February 25 07h00-17h00

The Scholars’ and Research Topics in Gastrointestinal (GI) Disease Programs (invitation only) will be held at the Fairmont Queen Elizabeth.

Registration Desk Hours – Foyer, Conference Level
Wednesday, February 24 08h00-20h30
Thursday, February 25 07h00-17h00

All core sessions of CDDW™ will be held at the Fairmont Queen Elizabeth. Registration Desk hours – Mezzanine Level
Thursday, February 25 17h00-21h00
Friday, February 26 07h00-18h30
Saturday, February 27 07h00-18h30
Sunday, February 28 07h30-18h30
Monday, February 29 07h30-14h00

EXHIBIT HOURS
The Exhibit and Trade Show will be held in the Le Grand Salon/Hochelagas 1-3 and will be open as follows:
Friday, February 26 09h30-18h30
Saturday, February 27 10h30-15h30
Sunday, February 28 10h30-15h30

SPEAKER READY ROOM
Please note that all speakers are asked to present themselves at the Speaker Ready Room, Saint Charles, at least two hours before their presentation.

Speaker Ready Room Hours
Thursday, February 25 17h00-21h00
Friday-Sunday, February 26-28 07h00-18h00
Monday, February 29 07h00-14h00

NO presentation preparation/loading for plenary sessions will be permitted to take place in rooms Marquette/Jolliett, Duluth or the Mackenzie. Breakfast and small group presentations may be loaded in those rooms.

CDDW™ IMPLEMENTATION COMMITTEE

- **Co-Chairs**
  - David Armstrong, CAG President Elect
  - Richard Schreiber, CASL President Elect

- **CAG Committee**
  - Derek McKay, Past Co-Chair
  - Kevin Waschke, Education
  - François Boudreau, Research
  - Wallace MacNaughton, Finance
  - Paul Sinclair, Executive Director

- **CASL Committee**
  - Eberhard Renner, Past Co-Chair
  - Hemant Shah, Education
  - Christopher Rose, Research
  - Kelly Burak, Finance

- **GRIT Course**
  - Mark Borgaonkar, Geoff Williams

- **Scholars’ Program**
  - Herbert Brill, Saumya Jayakumar

- **Research Topics in GI Disease**
  - Gilaad Kaplan, Elena Verdu

CDDW™ SPONSORS

- **Platinum**
  - AbbVie
  - Janssen Inc.

- **Gold Sponsors**
  - Allergan Canada
  - Olympus Canada
  - Takeda Canada, Inc.
  - Gilead Sciences Canada, Inc.
  - Merck Canada Inc.
  - Fairmont Queen Elizabeth

- **Silver Sponsors**
  - Pentax Medical
  - Bristol-Myers Squibb Canada

- **Bronze Sponsors**
  - Shire Pharma Canada ULC
  - Ferring Pharmaceuticals
  - Lupin Pharma Canada Ltd.

Centre Ice Gala – Sunday February 28
Pull on your favourite hockey jersey, and enjoy the company of fellow hockey fans as CDDW™ hosts the “Centre Ice Gala”. Treat your taste buds to the most exotic stadium cuisine, test out your stick handling skills, and skate the night away with tunes from our own Power Play DJ. Purchase tickets ($100 + tax) online and also at registration on-site.

CanMEDS ROLES
CanMEDS is a framework that identifies and describes the abilities physicians require to effectively meet the health care needs of the people they serve. These abilities are grouped thematically under seven roles: Medical Expert (the integrating role), Communicator, Collaborator, Leader, Health Advocate, Scholar and Professional. The CDDW™ program will include CanMEDS roles which will be identified at the beginning of each session. For more information on these newly revised definitions, visit:

ACCREDITATION
The CDDW™ Meeting is accredited as a group learning activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada (RCPSC) (as the conference overall includes at least 25% interactive time). See page 40 for a listing of credits per session. Financial support for sessions, as indicated within the program, is through educational grants. CDDW™ is in compliance with the CQDPCM (Quebec) Code of Ethics. For more information, please go to: http://www.cemqc.qc.ca/en/index_guide.cfm.

Live educational activities, occurring in Canada, recognized by the RCPSC as Accredited Group Learning Activities (Section 1) are deemed by the European Union of Medical Specialists eligible for ECMEC credits.

Through an agreement between the RCPSC and the American Medical Association, physicians may convert RCPSC MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert RCPSC MOC credit to AMA credit can be found at http://www.amaassn.org/go/internationalcme.

The 2016 CDDW™ is endorsed by:

Faculty who are American College of Gastroenterology Fellows or Masters are identified throughout the program by the * symbol.

CAG gratefully recognizes our Corporate Sponsors

- **Benefactors**
  - AbbVie
  - Allergan Canada
  - Olympus Canada
  - Janssen Inc.
  - Takeda Canada, Inc.
  - Pentax Medical
  - Merck Canada
  - Pfizer Canada Inc.

- **Partners**
  - Shire Pharma Canada ULC
  - Ferring Pharmaceuticals
  - Pendopharm
  - Vantage Endoscopy

- **Affiliate**
  - Procter & Gamble Professional

CASL gratefully recognizes our major sponsors:
- the Canadian Liver Foundation, its donors and members, and our industry partners: AbbVie, BMS, Gilead, Merck Canada, Astellas, KNS Canada, BTG International, and Pendopharm

CAG gratefully recognizes our Affiliate:

- Procter & Gamble Professional

CASL gratefully recognizes our Corporate Sponsors:

- **Benefactors**
  - AbbVie
  - Allergan Canada
  - Olympus Canada
  - Janssen Inc.
  - Takeda Canada, Inc.
  - Pentax Medical
  - Merck Canada
  - Pfizer Canada Inc.

- **Partners**
  - Shire Pharma Canada ULC
  - Ferring Pharmaceuticals
  - Pendopharm
  - Vantage Endoscopy

- **Affiliate**
  - Procter & Gamble Professional
<table>
<thead>
<tr>
<th>Time</th>
<th>Tuesday, February 23</th>
<th>Wednesday, February 24</th>
<th>Thursday, February 25</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AM</strong></td>
<td></td>
<td>Breakfast &amp; Small Groups</td>
<td>Breakfast</td>
</tr>
<tr>
<td></td>
<td>Poster Session I Cont’d &amp; Coffee</td>
<td>CDHF Session</td>
<td>CAG Overview</td>
</tr>
<tr>
<td><strong>MID-DAY</strong></td>
<td></td>
<td>Plenary Session II</td>
<td>Plenary Session IV</td>
</tr>
<tr>
<td></td>
<td>Lunch / Free time</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td><strong>PM</strong></td>
<td></td>
<td>Ivan T Beck Memorial Lectureship</td>
<td>Gastroenterology Jeopardy</td>
</tr>
<tr>
<td></td>
<td>Ice-Breaker Session</td>
<td>Dinner</td>
<td>Awards, Evaluation, Closing Remarks</td>
</tr>
<tr>
<td></td>
<td>Interactive Case Discussion</td>
<td>Plenary III</td>
<td>McKenna Memorial Lecturer</td>
</tr>
<tr>
<td></td>
<td>Plenary Session I</td>
<td>Plenary III</td>
<td>McKenna Memorial Lecturer</td>
</tr>
<tr>
<td></td>
<td>Dinner</td>
<td>CAG Young Educator Award Lecture</td>
<td>Reception</td>
</tr>
<tr>
<td></td>
<td>Expert Panel</td>
<td>Transition to Practice/Practice Management</td>
<td>Dinner</td>
</tr>
<tr>
<td></td>
<td>Poster Session I</td>
<td>Poster Session II</td>
<td></td>
</tr>
</tbody>
</table>

All sessions of the **GRIT Program** will be held at the Fairmont Queen Elizabeth.

**Session Learning Objectives:** The program is designed to foster communication between trainees in gastroenterology and hepatology, promote research for the residents, develop presentation skills, and deliver new knowledge in key areas related to the science and practice of gastroenterology and hepatology.
## GRIT PROGRAM

### TUESDAY, FEBRUARY 23

**Saint-Laurent/Gatineau Foyers**
12h00-15h00 Registration

**Saint-Maurice/Saint Charles**
15h00 Opening Remarks
– Mark Borgaonkar

15h15 Ice-Breaker Session
– Robert Berger

16h00 Interactive Case Discussion
– Leanna McKenzie and Robert Berger

16h45 Plenary Session I: Liver and Basic Science
– Mar Miserachs and Leanna McKenzie

**Marquette**
18h15 Dinner

**Saint-Maurice/Saint-Charles**
19h30 Expert Panel – ALL
Moderator:  Kevin Waschke

### WEDNESDAY, FEBRUARY 24

#### WEDNESDAY, FEBRUARY 24 Continued

**Duluth**
19h30 CAG Young Educator Award Lecture: Residents as Teachers *(with Scholars’ Program and Research Topics)*
– Geoff Williams

**Saint-Maurice/Saint-Charles**
20h15 Transition to Practice/Practice Management
– Robert Berger

**Hochelagas 4-6**
21h00 Poster Session II

### THURSDAY, FEBRUARY 25

**Foyer**
07h00 Breakfast

**Duluth**
08h00 CAG Overview
– David Armstrong

08h10 Canadian Digestive Health Foundation Session *(with Scholars’ Program and Research Topics)*

10h00 Coffee Break

**Saint-Maurice/Saint-Charles**
10h30 Plenary Session IV – Endoscopy
– Sarvenaz Moosavi and Kevin Waschke

**Marquette**
12h00 Lunch

**Saint-Maurice/Saint-Charles**
13h00 Ivan T Beck Lectureship: Using Epidemiology to Pursue Etiology in IBD
– Charles Bernstein

14h00 Gastroenterology Jeopardy
– Mark Borgaonkar and Veronique Morinville

15h00 Awards / Evaluation / Closing Remarks
– Kevin Waschke and Mark Borgaonkar

**Duluth**
16h00 McKenna Lecturer: An Academic Surgeon’s Views on GI Training *(with Scholars’ Program and Research Topics)*
– Johan Söderholm, Linkoping University

**Mackenzie**
17h00 Joint Reception

**Saint-François**
17h30 Joint Dinner

---

*Sponsored by the Fairmont Queen Elizabeth*
# SCHOLARS’ PROGRAM AT A GLANCE

<table>
<thead>
<tr>
<th></th>
<th><strong>Wednesday, February 24</strong></th>
<th><strong>Thursday, February 25</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AM</strong></td>
<td>Breakfast</td>
<td>CDHF Event</td>
</tr>
<tr>
<td></td>
<td>Life of a Gastroenterologist in Education</td>
<td>Life of a Community Gastroenterologist</td>
</tr>
<tr>
<td></td>
<td>Life of a Gastroenterologist in Research</td>
<td>Life of a Gastroenterologist in the U.S. vs. Canada</td>
</tr>
<tr>
<td></td>
<td>Panel Discussion</td>
<td></td>
</tr>
<tr>
<td><strong>MID-DAY</strong></td>
<td>Registration</td>
<td>Lunch and Endoscopy Challenge</td>
</tr>
<tr>
<td></td>
<td>Opening Remarks &amp; Introductions</td>
<td>Motility</td>
</tr>
<tr>
<td></td>
<td>Getting into a Gastroenterology Fellowship Program</td>
<td>Nutrition</td>
</tr>
<tr>
<td></td>
<td>Being a Gastroenterology Fellow</td>
<td>Pediatric Diseases</td>
</tr>
<tr>
<td></td>
<td>Transition from Fellow to Faculty</td>
<td>Panel Discussion</td>
</tr>
<tr>
<td></td>
<td>Financial Considerations in Gastroenterology</td>
<td>Closing Remarks</td>
</tr>
<tr>
<td></td>
<td>Panel Discussion</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Refreshment Break</td>
<td>McKenna Lecturer</td>
</tr>
<tr>
<td><strong>PM</strong></td>
<td>Critical Appraisal Skills</td>
<td></td>
</tr>
<tr>
<td></td>
<td>How to Prepare and Deliver an Effective Presentation</td>
<td>Reception</td>
</tr>
<tr>
<td></td>
<td>Ethical Issues</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Panel Discussion/Q&amp;A</td>
<td>Dinner</td>
</tr>
<tr>
<td></td>
<td>Working Dinner</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Advances in Gastrointestinal Imaging</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CAG Young Educator Award Lecture</td>
<td></td>
</tr>
</tbody>
</table>

All sessions of the **Scholars’ Program** will be held at the Fairmont Queen Elizabeth.

**Program Learning Objectives:** The Scholars’ Program is structured to identify exceptional medical students and PGY 1 and PGY 2 Internal Medicine and Pediatric Residents and to encourage them to consider a career in gastroenterology / hepatology. The program will educate the student/resident in the attributes required to enjoy a successful career in medicine, gastroenterology / hepatology and pediatrics. The candidate will have the opportunity to work with and learn from an internationally recognized academic and clinical faculty who are respected leaders and role models in the field.
### WEDNESDAY, FEBRUARY 24

**Day 1:** Welcome/Orientation and Planning a Career in Gastroenterology/Hepatology

**Foyer**
13h00-14h30 Registration

**Saint-Laurent**
14h30 Opening Remarks, Faculty and Student/Resident Introductions
   – Herbert Brill, Program Co-Chair
14h50 What Does It Take To Get into a Gastroenterology Fellowship Program?
   – Saumya Jayakumar, Program Co-Chair, and Herbert Brill
15h15 What Is It Like To Be a Gastroenterology Fellow?/What Are We (and programs) Looking For?
   – Yidan Lu
15h40 The Transition from Fellow to Faculty: Pleasures and Pitfalls
   – Constantine Soulellis
16h05 Financial Considerations for a Career in Gastroenterology
   – Herbert Brill
16h20 Panel Discussion – Gastroenterology Training
16h30 Refreshment Break
16h40 Critical Appraisal Skills
   – Mark Borgaonkar
17h10 How to Prepare and Deliver an Effective Presentation
   – Herbert Brill
17h40 Ethical Issues
   – Sylviane Forget
18h10 Panel Discussion/Q&A
18h30 Working Dinner
18h55 Advances in Gastrointestinal Imaging
   – Kevin Waschke

**Duluth**
19h30 CAG Young Educator Award Lecture: Residents as Teachers – Appropriate Bedside Teaching (with GRIT and Research Topics)
   – Geoff Williams

Adjournment following the Young Educator Award Lecture

### THURSDAY, FEBRUARY 25

**Day 2:** Clinical Advances in Gastroenterology/Hepatology and Lifestyles of a Gastroenterologist/Hepatologist

**Duluth**
07h00 Continental Breakfast

08h00 Canadian Digestive Health Foundation Session (with GRIT and Research Topics)

**Saint-Laurent**
10h00 Scholars' Program Opening Remarks
   – Saumya Jayakumar
10h10 The Life of a Gastroenterologist in Education
   – Geoff Williams
10h30 The Life of a Community Gastroenterologist
   – Chad Williams
10h50 The Life of a Gastroenterologist in Research
   – Alan Barkun
11h10 The Life of a Gastroenterologist in the U.S. vs. Canada
   – Harpreet Pall
11h30 Panel Discussion – Career Choices

**Duluth**
12h20 Advances in IBD
   – Charles Bernstein
12h50 Buffet Lunch
14h00 Motility
   – William Paterson
14h25 Nutrition
   – Johane Allard
14h50 Pediatric Diseases
   – Herbert Brill
15h15 Panel Discussion (faculty from previous four sessions)
15h30 Closing Remarks and Evaluation Completion
15h45 Refreshment Break

**Duluth**
16h00 McKenna Lecturer: An Academic Surgeon's Views on GI Training (with GRIT and Research Topics)
   – Johan Söderholm, Linkoping University

**Mackenzie**
17h00 Joint Reception

**Saint-François**
17h30 Joint Dinner

Note: Coffee and light refreshments will be in the back of the rooms on Wednesday, February 24 at 16h30 and Thursday, February 25 at 10h00 and 15h45.
WEDNESDAY, FEBRUARY 24

Foyer
11h00-14h30 Registration

Gatineau
14h30 Welcome/Introduction
   – Elena Verdu, Gilaad Kaplan
14h40 Clinical
   – Gilaad Kaplan, Stephanie Coward
      (6 orals – 13 min. each)
15h58 Microbial Pathogenesis of GI Disease
   – François Boudreau, Giada De Palma
      (5 orals – 13 min. each)
17h03 Pause santé
17h18 Liver and Cancer Pathogenesis and Disease
   – Carla Coffin, Giada De Palma
      (6 orals – 13 min. each)

Bersimis
18h36 Dinner

Duluth
19h30 CAG Young Educator Award Lecture: Residents as Teachers – Appropriate Bedside Teaching
   – Geoff Williams
   (with GRIT and Scholars)
20h15 Adjourn

THURSDAY, FEBRUARY 25

Foyer
07h00 Breakfast

Duluth
08h00 Canadian Digestive Health Foundation Session
   (with GRIT and Scholars)

Gatineau
10h15 Epithelium and Motor Pathophysiology
   – Premysl Bercik, Stephanie Coward
      (7 orals – 13 min. each)

Bersimis
11h46 Lunch

Gatineau
13h00 Pathogenesis and Potential Therapies for Colitis
   – Aida Fernandes, Giada De Palma
      (6 orals – 13 min. each)
14h18 Pause santé

Gatineau, Harricana, Chaudière
14h35 Career Development Session
   ‘What do I do with my degree and training: Work-life balance as a PI’
   Discussion sessions: 3 rotating groups
   ‘Clinician Scientist’ – Premysl Bercik, Carla Coffin
   ‘Clinical Research’ – Charles Bernstein
   ‘Outside of Academia’ – Aida Fernandes
      (28 min. for each session)

Duluth
16h00 McKenna Lecturer: An Academic Surgeon’s Views on GI Training
   – Johan Söderholm, Linköping University
   (with GRIT and Scholars)

Mackenzie
17h00 Joint Reception

Saint-François
17h30 Joint Dinner

CAG RESEARCH TOPICS IN GI DISEASE PROGRAM

Sponsored by the Canadian Institutes of Health Research
Institute of Nutrition, Metabolism and Diabetes
<table>
<thead>
<tr>
<th>Start</th>
<th>FRIDAY February 26</th>
<th>SATURDAY February 27</th>
<th>SUNDAY February 28</th>
<th>MONDAY February 29</th>
<th>Start</th>
</tr>
</thead>
<tbody>
<tr>
<td>07h00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>07h00</td>
</tr>
<tr>
<td>07h30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>07h30</td>
</tr>
<tr>
<td>08h00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>08h00</td>
</tr>
<tr>
<td>08h30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>08h30</td>
</tr>
<tr>
<td>09h00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>09h00</td>
</tr>
<tr>
<td>09h30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>09h30</td>
</tr>
<tr>
<td>10h00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>10h00</td>
</tr>
<tr>
<td>10h30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>10h30</td>
</tr>
<tr>
<td>11h00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>11h00</td>
</tr>
<tr>
<td>11h30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>11h30</td>
</tr>
<tr>
<td>12h00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>12h00</td>
</tr>
<tr>
<td>12h30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>12h30</td>
</tr>
<tr>
<td>13h00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>13h00</td>
</tr>
<tr>
<td>13h30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>13h30</td>
</tr>
<tr>
<td>14h00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>14h00</td>
</tr>
<tr>
<td>14h30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>14h30</td>
</tr>
<tr>
<td>15h00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>15h00</td>
</tr>
<tr>
<td>15h30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>15h30</td>
</tr>
<tr>
<td>16h00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>16h00</td>
</tr>
<tr>
<td>16h30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>16h30</td>
</tr>
<tr>
<td>17h00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>17h00</td>
</tr>
<tr>
<td>17h30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>17h30</td>
</tr>
<tr>
<td>18h00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>18h00</td>
</tr>
<tr>
<td>18h30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>18h30</td>
</tr>
<tr>
<td>19h00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>19h00</td>
</tr>
<tr>
<td>20h00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>20h00</td>
</tr>
<tr>
<td>21h00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>21h00</td>
</tr>
</tbody>
</table>

AGM annual general meeting; AILD autoimmune liver disease; CCC Crohn’s and Colitis Canada; CD Crohn’s disease; CLF Canadian Liver Foundation; GI gastrointestinal; *H pylori Helicobacter pylori; HCV hepatitis C virus; HRS hepatorenal syndrome; IBD inflammatory bowel disease; SBP spontaneous bacterial peritonitis

CAG/CCC AGM annual general meeting; AILD autoimmune liver disease; CCC Crohn’s and Colitis Canada; CD Crohn’s disease; CLF Canadian Liver Foundation; GI gastrointestinal; *H pylori Helicobacter pylori; HCV hepatitis C virus; HRS hepatorenal syndrome; IBD inflammatory bowel disease; SBP spontaneous bacterial peritonitis
OVERALL LEARNING OBJECTIVE FOR CDDW™ 2016
At the end of the conference delegates will be able to:
1. Identify evolving new areas of clinical and basic research in gastroenterology and hepatology.
2. Affirm through evaluation of the evidence that knowledge and management strategies are current.
3. Formulate management strategies for patients with gastrointestinal, including liver, disease.
4. Compare and contrast a wide variety of therapeutic approaches in the care of patients with gastrointestinal, including liver, diseases.
5. Recognize the importance of quality measures and patient safety initiatives in clinical and endoscopic practice.
6. Interact with colleagues to foster a community of practice.

CAG/CASL POSTGRADUATE COURSE
Specialists may be defined by their knowledge of the leading edge issues in gastroenterology and hepatology. The Postgraduate Course is intended to bring you up to date on developments in selected areas and get you ready for the challenges of 2016.

08h00-09h30
CAG/CASL POSTGRADUATE COURSE:
Community-based Gastrointestinal and Liver Disease
Marquette/Jolliet

Learning Objectives:
At the end of this session participants will be able to:
1. Review the selection of biologic agents to treat IBD and understand the role of combination therapy.
2. Discuss the time interval of endoscopic surveillance for: IBD-associated neoplasia, colonic polyps, and Barrett's esophagus.
3. Describe the staging of hepatitis C disease, and explore the role of community gastroenterologists in accessing and implementing new treatments.

Co-Chairs: Geoffrey Nguyen, University of Toronto and Kevork Peltekian, Dalhousie University

- Mirror, Mirror on the Wall, Which Biologic Combo Will Fare Best of All?
  Brian Bressler, University of British Columbia

- Timing is Everything: How often should we perform endoscopic surveillance?
  Marietta Iacucci, University of Calgary

- Charging the Frontlines: Real world challenges with the new hepatitis C therapy
  Hemant Shah, University of Toronto

  – CAG co-developed this program with Bristol-Myers Squibb Canada to achieve scientific integrity, objectivity and balance –

08h00-09h30
†CAG SYMPOSIUM:
IBD Microbiota
Mackenzie

Learning Objectives:
At the end of this session participants will be able to:
1. Understand the complexity of dietary-microbiota interactions and the role they play in modulation of intestinal inflammation.
2. Discuss the role of bacterial anti-fungal dysbiosis in IBD.
3. Review the current therapies and levels of evidence regarding therapies targeting the microbiome in IBD.

Co-Chairs: Michael Surette, McMaster University and Elena Verdu, McMaster University

- Diet-Microbiota Interactions in IBD: From basics to clinics
  Karen Madsen, University of Alberta

- Beyond Bacterial Dysbiosis: Fungal signature in IBD
  Frederic Bushman, University of Pennsylvania

- Microbiota Directed Therapies for IBD: Focus on transplantation
  Paul Moayyedi*, McMaster University

* American College of Gastroenterology Fellow or Master
† Session includes oral presentations of key abstracts
FRIDAY FEBRUARY 26

- Determinants of intestinal permeability in healthy first degree relatives of Crohn's disease patients (Abstract 1)
  - W Turpin1, D Kevans1, K Shestopaloff1, M Smith1, D Gutman1, MS Silverberg1, W Xu1, A Paterson1, K Croitoru1
  1Mount Sinai Hospital, Toronto, Ontario; 2University of Toronto, Toronto, Ontario; 3Dalla Lana School of Public Health, Toronto, Ontario; 4The Hospital for Sick Children, Toronto, Ontario

09h30-15h00

ASGE VIDEO CENTRE & EPORTAL CENTRE (See pages 31-32)

09h30-10h00

Exhibits and Nutrition Break

10h00-11h30

CAG/CASL POSTGRADUATE COURSE

Inpatient Hepatology

Marquette/Jolliet

Learning Objectives:
At the end of this session participants will be able to:
1. Develop an approach to pre-operative assessment and optimization for the liver patient undergoing non-liver procedures.
2. Apply a stepwise approach in encephalopathy management in their practice.
3. Explore the benefits and risks of therapies for alcoholic hepatitis.

Co-Chairs: Hemant Shah, University of Toronto and Jeffrey So, Halton Healthcare
- Preparing the Patient with Liver Disease for Surgery: Risk assessment and optimization
  Rohit Loomba, University of California, San Diego
- Reducing the Confusion around Managing Hepatic Encephalopathy: Update on treatment
  Philip Wong, McGill University
- Controversies and Clarity in Managing Acute Alcoholic Hepatitis
  Meredith Borman, University of Calgary
  - CAG co-developed this program with Bristol-Myers Squibb Canada to achieve scientific integrity, objectivity and balance –

10h00-11h30

†CAG/CROHN’S AND COLITIS CANADA

STUDENT PRIZE PAPER PRESENTATIONS

Mackenzie

Co-Chairs: Aida Fernandes, Crohn’s and Colitis Canada (CCC) and François Boudreau, Université de Sherbrooke

CAG Student Prize
- Integrin α1β1 is controlled by the MYC oncogenic factor and confers pro-proliferative and pro-migratory advantage to colorectal cancer cells (Abstract 2)
  - S Boudjadi2, G Bernatchez2, B Senicourt1, M Beauséjour2, PH Vachon2, J Carrier2, J Beaulieu2
  1Université de Sherbrooke, Sherbrooke, Québec; 2Anatomie et Biologie Cellulaire, Université de Sherbrooke, Sherbrooke, Québec

CAG Student Prize
- Role of the phosphatase DUSP6 in the control of intestinal tumorigenesis and inflammation (Abstract 3)
  - K Beaudry, A Montagne, M Langlois, S Cagnol, N Rivard
  Université de Sherbrooke, Sherbrooke, Québec

CAG Student Prize
- Fecal immunochemical testing and fecal calprotectin predict mucosal healing in inflammatory bowel disease: A prospective study (Abstract 4)
  - C Ma, R Lumb, RR Foshaug, T Dang, S Verma, V Huang, KJ Kroeker, K Wong, LA Dieleman, BP Halloran, RF Fedorak
  University of Alberta, Edmonton, Alberta

CCC Student Prize
- The interaction between NOD2 and smoking is specific to the 1007fs SNP of the NOD2 gene in Crohn’s disease: A systematic review and meta-analysis (Abstract 5)
  - E Kuenzig3, B Eksteen2, HW Barkema2, C Seow2, C Barnabe2, MS Silverberg1, P Lakatos2, R Panaccione2, SG Ghosh2, GG Kaplan4

* American College of Gastroenterology Fellow or Master
† Session includes oral presentations of key abstracts
FRIDAY FEBRUARY 26

**CCC Student Prize**
- Intravenous immunoglobulin-induced regulatory macrophages produce IL-10 and may be useful to treat inflammatory bowel disease (Abstract 6)
  - L Kozicky, S Menzies, LM Sly
  - University of British Columbia, Vancouver, British Columbia

**Learning Objectives:**
At the end of this session participants will be able to:
1. Explore innovations in the clinical care of patients with complex gastrointestinal disease.
2. Evaluate new information related to advances in the treatment of gastrointestinal diseases.
3. Recognize new directions in research into the management and care of patients with GI illness.

**Co-Chairs:** Grigoris Leontiadis, McMaster University and Jill Tinmouth, University of Toronto

- Trends in incidence of pediatric inflammatory bowel disease in Canada: Population-based estimates from the Canadian Gastrointestinal Epidemiology Consortium (CanGIEC) (Abstract 7)
  - EI Benchimol1, CN Bernstein2, A Bitton3, MW Carroll4, W El-Matary5, A Otley6, H Singh7, GC Nguyen7, A Griffiths8, DR Mack9, N Mojaiverian10, M Vutcovici11, Y Cui12, Z Nugent8, D Tanyingoh6, GG Kaplan6
  - 1University of Alberta, Edmonton, Alberta; 2University of Ottawa, Ottawa, Ontario; 3University of Manitoba, Winnipeg, Manitoba; 4Royal Victoria Hospital, McGill University, Montréal, Québec; 5Pediatrics, Dalhousie University, Halifax, Nova Scotia; 6Gastroenterology, McGill University, Montréal, Québec; 7Pediatrics, University of Ottawa/CHEO, Ottawa, Ontario; 8Pediatric Gastroenterology and Nutrition, IWK Health Centre, Halifax, Nova Scotia

- Steroid-free remission among Canadian pediatric inflammatory bowel disease patients (Abstract 8)
  - PC Church1, T Walters1, EI Benchimol2, K Jacobson3, W El-Matary4, C Deslandres5, H Huynh6, M Carroll5, E Wine7, DR Mack8, J Van Limbergen9, A Otley5, A Griffiths8
  - 1The Hospital for Sick Children, Toronto, Ontario; 2BC Children's Hospital, Vancouver, British Columbia; 3University of Manitoba, Winnipeg, Manitoba; 4Service de gastro-entérologie, Hôpital Sainte-Justine, Montréal, Québec; 5Stollery Children's Hospital, Edmonton, Alberta; 6Pediatrics, University of Ottawa/CHEO, Ottawa, Ontario; 7Pediatric Gastroenterology and Nutrition, IWK Health Centre, Halifax, Nova Scotia

- A randomized comparison of high definition colonoscopy alone with high definition dye spraying chromoendoscopy and electronic virtual chromoendoscopy using iSCAN for detection of colonic dysplastic lesions during IBD surveillance (Abstract 9)
  - M Iacuccii1, M Fort Gasia2, R Panacecione1, A Oluseyi1, S Urbianski2, M Parham2, S Ghosh3
  - 1Gastroenterology and 2Department of Pathology – University of Calgary, Calgary, Alberta

- A virtual reality curriculum in non-technical skills improves performance in colonoscopy: A randomized trial (Abstract 10)
  - SC Grover1, MA Scaffidi1, B Chana1, K Gupta1, M Zasowski1, O Zarghom1, C Dargavel1, T Alomani1, A Kamani1, S Sharma1, CM Walsh2
  - 1Gastroenterology, University of Toronto, Toronto, Ontario; 2Gastroenterology, Hepatology and Nutrition, Hospital for Sick Children and The Wilson Centre, Toronto, Ontario

- Cost-effectiveness of Hemospray™ in patients with non variceal upper gastrointestinal bleeding (Abstract 11)
  - AN Barkun*1, V Adam, Y Chen, Y Lu, M Martel
  - McGill University, Montréal, Québec

- New oral anticoagulants and gastrointestinal hemorrhage: A systematic review and meta-analysis (Abstract 12)
  - A Dorreen1, C Miller1, M Martel2, AN Barkun3
  - 1Dalhousie University, Halifax, Nova Scotia; 2McGill University Health Center, Montréal, Québec; 3Gastroenterology, McGill University, The Montreal General Hospital, GI Division, Montréal, Québec

* American College of Gastroenterology Fellow or Master
† Session includes oral presentations of key abstracts
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>11h30-12h30</td>
<td>Exhibits and Lunch</td>
<td>Le Grand Salon/Hochelagas 1-3</td>
</tr>
<tr>
<td>12h30-14h30</td>
<td>CAG/CASL POSTGRADUATE COURSE</td>
<td>Marquette/Jolliet</td>
</tr>
<tr>
<td></td>
<td>Safety Monitoring</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Learning Objectives:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>At the end of this session participants will be able to:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1. List addressable causes of interval colon cancers and adapt their endoscopic practices accordingly.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2. Compare and contrast the risk-benefits of long-term proton pump inhibitor use.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3. Appreciate the possible impact of carbapenem-resistant <em>Enterobacteriaceae</em> on current endoscopic disinfection processes.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Co-Chairs: Alan Barkun*, McGill University and Dan Sadowski, University of Alberta</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Interval Colon Cancer: How many cancers are we missing and why?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Linda Rabeneck*, Colon Cancer Ontario</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Long-Term Risks of Proton Pump Inhibitors: What should I tell my patient?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Grigoris Leontiadis, McMaster University</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• How to Keep your Endoscopy Unit out of the Headlines</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Adam Slivka, University of Pittsburgh</td>
<td></td>
</tr>
<tr>
<td>12h30-14h30</td>
<td>†CAG SYMPOSIUM:</td>
<td>Mackenzie</td>
</tr>
<tr>
<td></td>
<td>Cellular Reprogramming in Gastrointestinal Diseases</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Learning Objectives:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>At the end of this session participants will be able to:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1. Outline new and cutting edge techniques that facilitate the study of GI disease.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2. Describe new approaches to grow and manipulate GI epithelia as well as intestinal stem cells.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3. Use 3D cell cultures and organoids to answer key questions in GI research.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Co-Chairs: Nathalie Perreault, Université de Sherbrooke and Bruce Vallance, University of British Columbia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Manipulating Gastric Organoids in the Study of Gastric Pathophysiology following Infection</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nicola Jones, University of Toronto</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• The gut microbiota-dependent metabolite, TMAO, protects against colitis: A role for the inhibition of apoptosis? (Abstract 13)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>– A Al Rajabi, A Wang, DM McKay</td>
<td></td>
</tr>
<tr>
<td></td>
<td>University of Calgary, Calgary, Alberta</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Three-dimensional Organotypic Culture to Study Esophageal Diseases</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Marie-Pier Tetreault, Northwestern University</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Effects of milk lipid globule membrane on post-natal intestinal development (Abstract 14)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>– G Bhinder, R Dyer, S Innis, B Vallance</td>
<td></td>
</tr>
<tr>
<td></td>
<td>University of British Columbia, Vancouver, British Columbia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Defining the Structure of the Intestinal Ecosystem by Host-microbial Interactions</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Thaddeus Stappenbeck, Washington University in St. Louis</td>
<td></td>
</tr>
</tbody>
</table>

* American College of Gastroenterology Fellow or Master
† Session includes oral presentations of key abstracts
FRIDAY FEBRUARY 26

15h00-16h30  CAG/CASL POSTGRADUATE COURSE
             Video Endoscopy
             Marquette/Jolliet

Learning Objectives:
At the end of this session participants will be able to:
1. Describe three techniques for improved visualization of dysplasia during colonoscopy and discuss ways to implement changes in their own practice to improve dysplasia detection.
2. Outline the potential benefits and challenges of peroral endoscopic myotomy (POEM) vs. surgical or balloon dilation approach to achalasia.
3. Explore how to implement recent advances in endoscopic training into their endoscopic practice.

Co-Chairs: Lawrence Hookey, Queen’s University and Kevin Waschke, McGill University

- Advances in Endoscopic Imaging and Diagnosis
  Ralf Kiesslich, Johannes Gutenberg University of Mainz

- POEM: The New Standard for the Treatment of Achalasia?
  Robert Bechara, Queen’s University

- Advances in Endoscopic Imaging
  Kevin Waschke

15h00-16h30  CAG SYMPOSIUM:
             †Colonic Motility
             Mackenzie

Learning Objectives:
At the end of this session participants will:
1. Recognize the latest developments in high resolution manometry of the human colon and its clinical significance.
2. Be aware of the current hypotheses as to mechanisms underlying colonic motility in animal models and humans.
3. Describe the intrinsic and extrinsic innervation of the colon, its role in motility control and changes occurring during inflammation.

Co-Chairs: Christopher Andrews, University of Calgary and Jan Huizinga, McMaster University

- Resolving Colonic Dysmotility Using High Resolution Colonic Manometry
  Philip Dinning, Flinders University, South Australia

- Mechanisms Underlying Colonic Motility
  Jan Huizinga

- Mesotrypsin evokes PAR2 dependent excitability of nociceptive dorsal root ganglia (DRG) neurons
  (Abstract 15)
  - CD Lopez Lopez¹, J O Jaramillo Polanco¹, C Rolland-Fourcade², N Vergnolle², S Vanner¹
  ¹Gastrointestinal Diseases Research Unit, Queen’s University, Kingston, Ontario; ²INSE R UMR-1043, Toulouse, France

- Neural Regulation of Colonic Motility
  Alan Lomax, Queen’s University

16h30-17h30  CAG ANNUAL GENERAL MEETING
             Mackenzie

16h30-17h30  CASL ANNUAL GENERAL MEETING
             Duluth

* American College of Gastroenterology Fellow or Master
† Session includes oral presentations of key abstracts
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>17h30-18h30</td>
<td>CDDW™ OPENING RECEPTION</td>
<td>Le Grand Salon/Hochelagas 1-3</td>
</tr>
<tr>
<td></td>
<td>The conference showcases the latest, cutting-edge products, equipment and services for gastroenterology clinicians and researchers. Exhibitors include companies from the pharmaceutical and food industry as well as the device/instrumentation sector, not-for-profits, and charitable organizations. We invite you to help us open the meeting, take time to get to know the exhibitors and their offerings, and catch up with colleagues while enjoying complimentary drinks and hors d’œuvres. <strong>Give a note of thanks to our sponsors and exhibitors as without their critical support this meeting would not be possible!</strong> While at each exhibit booth have your badge scanned to be entered into a contest for a chance to win 1 of 12 room nights at the Fairmont Banff Springs (base room and taxes) for CDDW™ 2017.</td>
<td></td>
</tr>
<tr>
<td>18h30-20h00</td>
<td>TRAINEE MIXER</td>
<td>Saint-Maurice</td>
</tr>
<tr>
<td></td>
<td>New this year we are offering trainees the opportuntiy to mix and mingle with others who are at a similar stage in their career development. Whether you are a graduate student, medical student, resident or post-doctoral fellow, come meet your colleagues from across Canada to compare notes on your research, career aspirations or next steps. We respectfully ask that only trainees take part in this mixer. Light snacks and beverages (bring your drink tickets) will be served.</td>
<td></td>
</tr>
</tbody>
</table>
SATURDAY FEBRUARY 27

07h00-08h00 Challenges in Gastroenterology and GI Research – Open Mic Session
Duluth
Come lend your voice to identify and brainstorm solutions to the key issues facing digestive health care and GI research in Canada. Last year's session provided useful direction to CAG's Human Resources Task Force; help us continue their initiative and expand the focus while enjoying a hot breakfast.

07h00-09h00 Morning Coffee, supported by the Canadian Digestive Health Foundation
Booth 2001

08h00-09h00 CAG BREAKFAST WITH THE EXPERTS
Chaudière
Celiac Disease: Case based

Learning Objectives:
At the end of this session participants will be able to:
1. Describe the association of celiac disease with other autoimmune disorders.
2. List the differential diagnosis in patients with celiac disease when there are conflicting investigations.
3. Identify the appropriate treatment monitoring in celiac disease.

Speakers: Mohsin Rashid, Dalhousie University and Alaa Rostom, University of Ottawa

Please note that pre-registration is required to gain admittance to Breakfast with the Experts

08h00-09h00 CAG BREAKFAST WITH THE EXPERTS
Matapédia
Barrett's Esophagus

Learning Objectives:
At the end of this session, participants will be able to:
1. Recognize the role of the various modalities used in the diagnosis and staging of high-grade dysplasia and early esophageal adenocarcinoma.
2. Identify the indications, benefits and complications of the available endoscopic techniques in the treatment of high-grade dysplasia and early neoplasm.
3. Appreciate the need for adequate long-term follow-up of patients successfully treated by endoscopic ablation.

Speakers: Ralf Kiesslich, Johannes Gutenberg University of Mainz and Serge Mayrand, McGill University

Please note that pre-registration is required to gain admittance to Breakfast with the Experts

08h00-09h00 CASL BREAKFAST WITH THE EXPERTS
Harricana
Difficult Autoimmune Liver Disease (AILD) Cases

Learning Objectives:
At the end of this session, participants will be able to:
1. Recognize the effects of IBD on primary sclerosing cholangitis outcomes.
2. Be aware of the role of IgG4 in biliary disease.
3. Discuss the use of rituximab in complex AILD.

Speakers: Angela Cheung, University of Toronto and Bertus Eksteen, University of Calgary

Please note that pre-registration is required to gain admittance to Breakfast with the Experts

08h00-10h00 †CAG SYMPOSIUM:
Mackenzie
Epigenetics of Gastrointestinal Cancer

Learning Objectives:
At the end of this session participants will be able to:
1. Identify the role of epigenetics in the development and progression of GI cancers.
2. List potential epigenetic biomarkers and therapeutic targets for GI cancers.
3. Describe how nutritional epigenetics influences GI cancers.

Co-Chairs: Young-In Kim, University of Toronto and Isabella Tai, University of British Columbia
Learning Objectives:
At the end of this session participants will be able to:
1. Explore innovations in the clinical care of patients with complex liver disease.
2. Evaluate new information related to advances in the treatment of liver disease.
3. Recognize new directions in research into the management and care of patients with liver disease.

CASL Student Prize

- Prevalence and factors associated with nonalcoholic fatty liver disease as diagnosed by transient elastography with controlled attenuation parameter in HIV mono-infected patients (Abstract 18)
  
  E Vuille-Lessard, L Lennox, C Pexos, B Lebouche, MB Klein, G Sebastiani
  
  Royal Victoria Hospital, McGill University Health Center, Montréal, Québec

- Minimal hepatic encephalopathy renders the brain susceptible to hypotension-induced neuronal cell loss in BDL rats (Abstract 19)
  
  M Clément1, CR Bosoi1, M Tremblay1, C Bemeur2, CF Rose1
  
  1CRCHUM, Montréal, Québec; 2Nutrition, Université de Montréal, Montréal, Québec

- Risk factors and outcomes of non-skin cancers after liver transplantation for primary sclerosing cholangitis (Abstract 20)
  
  MA Mouchli, S Singh, JA Talwalkar, EV Loftus, C Rosen, J Heimbach, RH Wiesner, K Watt, JJ Poterucha
  
  Mayo Clinic, Rochester, Minnesota

- Cirrhotic patients with sarcopenia and sarcopenic-obesity have an increased risk of hyperammonemia and hepatic encephalopathy (Abstract 21)
  
  AJ Montano-Loza3, A Duarte-Rojo4, RA Bhanji2, CF Rose1
  
  1Hôpital St-Luc, CRCHUM, Université de Montréal, Montréal, Québec; 2University of Alberta, Edmonton, Alberta; 3Division of Gastroenterology & Liver Unit, University of Alberta, Edmonton, Alberta; 4University of Arkansas for Medical Sciences, Little Rock, Arkansas

- Reduced hepatic PGC-1α leads to oxidative stress and worsened NAFLD progression (Abstract 22)
  
  A Besse-Patin, JL Estall
  
  Mécanismes Moléculaires du Diabète, Institut de Recherches Cliniques de Montréal, Montréal, Québec

- Post-transplant cholestasis within 1-year predicts PSC recurrence (Abstract 23)
  
  S Wasilenko1, E Lytvyak2, AJ Montano-Loza2, AL Mason2
  
  1University of Alberta, Edmonton, Alberta; 2Division of Gastroenterology & Liver Unit, University of Alberta, Edmonton, Alberta

  – CAG co-developed this program with Lupin Pharma Canada Ltd. to achieve scientific integrity, objectivity and balance –
SATURDAY FEBRUARY 27

09h00-10h00  CAG SYMPOSIUM  Marquette/Jolliet
**Precision Medicine as an Emerging Theme in Gastroenterology**

**Learning Objectives:**
At the end of this session participants will be able to:

1. Consider the implications for new biomarkers to tailor the care of digestive disorders in Canada in the coming decade.
2. Recognize how best to stay updated and maintain the skill-set required for gastroenterology healthcare providers in 2020.

**Co-Chairs:** Jonathan Meddings, University of Calgary and Philip Sherman, Canadian Institutes of Health Research

- Update: CIHR Institute of Nutrition, Metabolism and Diabetes Refreshed Strategic Plan 2015-2018
  Philip Sherman

- The Future of Precision Medicine in Gastroenterology
  Jane Aubin, Canadian Institutes of Health Research

- How will Precision Medicine Change Education and Research in Gastroenterology?
  Nicola Jones, University of Toronto
  – CAG co-developed this program with the Canadian Institutes of Health Research Institute of Nutrition, Metabolism and Diabetes to achieve scientific integrity, objectivity and balance –

10h00-10h30  CLF-CASL GOLD MEDAL LECTURE  Marquette/Jolliet

**A Personal Journey Through the History of Hepatology: The Role of Good Fortune**
Morris Sherman*, University of Toronto
– Introduction by Eberhard Renner

10h30-15h30  ASGE VIDEO CENTRE & EPORTAL CENTRE (See pages 31-32)  Saint-Charles

10h30-11h00  Exhibits and Nutrition Break  Le Grand Salon/Hochelagas 1-3

11h00-11h40  SMALL GROUP SESSIONS (See details on pages 33-39)  Riche lieu

SEE (Skills Enhancement for Endoscopy): Practical tips
(CAG co-developed this program with Olympus Canada to achieve scientific integrity, objectivity and balance)

SEE: Practical tips
(CAG co-developed this program with PENTAX Medical to achieve scientific integrity, objectivity and balance)

Investigation of the Small Bowel
(CAG co-developed this program with Olympus Canada to achieve scientific integrity, objectivity and balance)

Ultrasound and IBD
(CAG co-developed this program with Merck Canada Inc. to achieve scientific integrity, objectivity and balance)

Refractory En copresis in Pediatrics

Work-Life Balance Issues

Interventional EUS
(CAG co-developed this program with Olympus Canada to achieve scientific integrity, objectivity and balance)

Infection Models

Case Discussions in Pediatric Chronic Viral Hepatitis
(CAG co-developed this program with Merck Canada Inc. to achieve scientific integrity, objectivity and balance)

Thrombosis and Liver Disease - When to anticoagulate

HIV and Liver Transplant - Outcomes, barriers and what to expect

Please note that pre-registration is required to gain admittance to Small Group Sessions

* American College of Gastroenterology Fellow or Master
† Session includes oral presentations of key abstracts
**SATURDAY FEBRUARY 27**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>11h40-11h50</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>11h50-12h30</td>
<td>SMALL GROUP SESSIONS (See details on pages 33-39)</td>
<td>Richelieu, Saint Laurent, Kamouraska 1+2, Kamouraska 1+2, Ramezay, Péribonka</td>
</tr>
<tr>
<td></td>
<td><strong>SEE: Practical tips</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(CAG co-developed this program with Olympus Canada</td>
<td></td>
</tr>
<tr>
<td></td>
<td>to achieve scientific integrity, objectivity and balance)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Updates in Fecal Microbiota Transplant</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Colonic Motility</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Early Onset IBD in Pediatrics</td>
<td>Bersimis</td>
</tr>
<tr>
<td></td>
<td>(CAG co-developed this program with Janssen Inc.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>to achieve scientific integrity, objectivity and balance)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Marijuana and GI Disease</td>
<td>Ramezay</td>
</tr>
<tr>
<td></td>
<td>Colonic Polypectomy</td>
<td>Péribonka</td>
</tr>
<tr>
<td></td>
<td>CDHF Session: Protecting the Human Gut Microbiota to Enhance Health</td>
<td>Youville 1+2</td>
</tr>
<tr>
<td></td>
<td>(CAG co-developed this program with Shire Pharma Canada ULC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>to achieve scientific integrity, objectivity and balance)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Acute on Chronic Liver Failure - When is the patient too sick for transplant?</td>
<td>Chaudière</td>
</tr>
<tr>
<td></td>
<td>Lean Non-alcoholic Fatty Liver Disease (NAFLD) - Is it Different than Obese NAFLD?</td>
<td>Matapédia</td>
</tr>
<tr>
<td></td>
<td>Intermediate Stage HCC - What to Do?</td>
<td>Harricana</td>
</tr>
</tbody>
</table>

Please note that pre-registration is required to gain admittance to Small Group Sessions

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>12h30-13h30</td>
<td>Exhibits and Lunch</td>
<td>Le Grand Salon/Hochelagas 1-3</td>
</tr>
<tr>
<td>13h30-15h00</td>
<td>CIHR-CAG SYMPOSIUM</td>
<td>Marquette/Jolliet</td>
</tr>
<tr>
<td></td>
<td><strong>The Role of Nutrition in Gastroenterology</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Learning Objectives:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>At the end of this session participants will be able to:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1. Describe dietary interventions for GI symptoms and food intolerance.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2. Be aware of the low-FODMAP diet.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3. Have insight into a holistic analysis of eating patterns as opposed to a more “bean counting approach”.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>4. Discuss case-based strategies to combat malnutrition in hospitalized patients.</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Co-Chairs:</strong> Leah Gramlich, University of Alberta and Khursheed Jeejeebhoy, University of Toronto</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Bloating, Functional Bowel Disease and Food Sensitivity: Non-celiac gluten sensitivity, the low FODMAP diet and beyond? Low FODMAP diet and the future of food intolerance</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Peter Gibson, Monash University</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• The Practical Dietary Guidelines</td>
<td>Jean-Claude Moubarac, Université de Montréal</td>
</tr>
<tr>
<td></td>
<td>• The Role of the Gastroenterologist in Hospital Malnutrition</td>
<td>Leah Gramlich and Khursheed Jeejeebhoy</td>
</tr>
<tr>
<td></td>
<td>– CAG co-developed this program with the Canadian Institutes of Health Research Institute of Nutrition, Metabolism and Diabetes to achieve scientific integrity, objectivity and balance –</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Location</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>13h30-15h00</td>
<td>CASL SYMPOSIUM</td>
<td>Duluth</td>
</tr>
<tr>
<td></td>
<td><strong>Updates in Pediatric Cholestasis</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Learning Objectives:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>At the end of this session participants will be able to:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1. Identify the role of non-invasive markers of fibrosis and inflammation in primary sclerosing cholangitis.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2. Recognize recent advances in the genetics and therapeutics of progressive familial intrahepatic cholestasis.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3. Explore physiological roles, and therapeutic targets, for bile acid-mediated regulation of metabolism in liver and intestine that impact upon NAFLD and cholestatic disorders.</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Co-Chairs:</strong> Binita Kamath, University of Toronto and Richard Schreiber, University of British Columbia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Primary Sclerosing Cholangitis: Monitoring and surveillance for teens in the modern era</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bertus Eksteen, University of Calgary</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Updates in Progressive Familial Intrahepatic Cholestasis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Binita Kamath</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Bile Acid-based Therapeutics for Liver and Obesity-related Disorders</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Saul Karpen, Emory University</td>
<td></td>
</tr>
<tr>
<td>13h30-15h00</td>
<td>RESEARCH CAREER DEVELOPMENT</td>
<td>Mackenzie</td>
</tr>
<tr>
<td></td>
<td><strong>Learning Objectives:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>At the end of this session participants will:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1. Have a better understanding of career paths inside and outside of academia.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2. Be better equipped to seek and secure a productive post-doctoral fellowship.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3. Be able to recognize and foster the development of marketable skills beyond those learned in the lab.</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Co-Chairs:</strong> Simon Hirota, University of Calgary and Martin Stahl, University of British Columbia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• How to Get the Most Out of Your Postdoctoral Fellowship</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Simon Hirota/Martin Stahl</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Views from Industry: Insight into a career outside of academia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ryan Conder, STEMCELL Technologies</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• I am a Scientist and I Play One on TV</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jennifer Gardy, University of British Columbia</td>
<td></td>
</tr>
<tr>
<td>15h00-15h30</td>
<td>Exhibits and Nutrition Break</td>
<td>Le Grand Salon/Hochelagis 1-3</td>
</tr>
<tr>
<td>15h30-16h30</td>
<td>KOPEMAN LECTURE</td>
<td>Mackenzie</td>
</tr>
<tr>
<td></td>
<td><strong>Pediatric IBD: Integrating clinical care and research</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Anne Griffiths, University of Toronto</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Introduction by Decker Butzner</td>
<td></td>
</tr>
</tbody>
</table>
CAG SYMPOSIUM

Monitoring Disease Activity in IBD

Marquette/Jolliet

Learning Objectives:
At the end of this session participants will be able to:
1. Recognize the role of patient experience and identify the utility of patient report approaches in the assessment of disease activity in patients with IBD.
2. Identify the operating characteristics of serum and fecal inflammatory biomarkers for assessment of disease activity in patients with IBD.
3. Determine the role of endoscopic and radiologic evaluation in the assessment of disease activity in patients with IBD.

Co-Chairs: Waqqas Aff, McGill University and Charles Bernstein*, University of Manitoba

- Stress, Clinical Symptoms and Patient Report in the Assessment of Disease Activity in IBD
  Lesley Graff, University of Manitoba
- Serum and Stool Markers in the Assessment of Disease Activity in IBD
  Edward Loftus*, Mayo Clinic, Rochester
- Radiology and Endoscopy in the Assessment of Disease Activity in IBD
  Talat Bessissow, McGill University
- Panel Discussion/Cases
  – CAG co-developed this program with AbbVie to achieve scientific integrity, objectivity and balance –

CASL SYMPOSIUM

Optimizing Fatty Liver Outcomes

Duluth

Learning Objectives:
At the end of this session participants will be able to:
1. Evaluate the evidence base for current fatty liver treatments.
2. Recognize the role of non-medical management for nonalcoholic steatohepatitis.
3. Appreciate that fatty liver is more than a liver disease.

Co-Chairs: Melanie Beaton, Western University and Saumya Jayakumar, University of Calgary

- Treatment Options for NAFLD: Current and practical management considerations for your practice
  Rohit Loomba, University of California, San Diego
- Bariatric Surgery for NAFLD
  Bandar Al-Judaibi, Western University
- Extrahepatic Complications of NAFLD
  Keyur Patel, University of Toronto

MCKENNA RECEPTION

Conference Level Foyer

17h00-17h30

RD MCKENNA MEMORIAL LECTURE

Working on the Barrier

Marquette/Jolliet

Johan Söderholm, Linköping University
– Introduction by Derek McKay

Immediately preceding the McKenna Lecture there will be a short presentation of the Canadian Association of Gastroenterology Fellows (CAGF) inducted for 2016. CAGF is an esteemed honour for CAG members who have demonstrated long-term commitment to the Association and to furthering the goals of advancing gastroenterology practice and GI research in Canada
SUNDAY FEBRUARY 27

18h30-20h00

POSTER SESSION 1
Hochelagas 4-6/Saguenay/Saint-Maurice

Join authors and colleagues in relaxed and informative discussions while enjoying beverages and light snacks. Please be sure to see the Posters of Distinction (A35, A82, A100, A115-A123, A152, A156) located throughout the poster area and identified with a ribbon.
**Difficult Cases in Crohn's Disease**

**Learning Objectives:**
At the end of this session participants will be able to:
1. Identify options for assessing for postoperative recurrence of Crohn’s disease.
2. Recognize the utility of therapeutic drug monitoring in individuals with recurrent Crohn’s disease on biologic therapy.
3. Discuss medical options for individuals with anti-TNF refractory (or anti-TNF intolerant) Crohn’s disease.

Speakers: Edward Loftus*, Mayo Clinic, Rochester and Chad Williams, Saint John

*Please note that pre-registration is required to gain admittance to Breakfast with the Experts*

**Advances in Helicobacter pylori Therapeutics**

**Learning Objectives:**
At the end of this session participants will be able to:
1. Describe the two main new CAG/Canadian Helicobacter Study Group recommended options for first line therapy of \( H. pylori \) infection.
2. Explain choices for second line therapy depending on the treatment that previously failed.
3. Recognize the treatment algorithm for \( H. pylori \) as recommended by the CAG/Canadian Helicobacter Study Group.

Speakers: Naoki Chiba, McMaster University and Carlo Fallone, McGill University

*Please note that pre-registration is required to gain admittance to Breakfast with the Experts*

**HRS and SBP: Tips and tricks**

**Learning Objectives:**
At the end of this session participants will be able to:
1. Identify best practices in managing hepatorenal syndrome and spontaneous bacterial peritonitis.
2. Review common pitfalls in management and develop strategies that address them.

Speakers: Puneeta Tandon, University of Alberta and Cynthia Tsien, University of Toronto

*Please note that pre-registration is required to gain admittance to Breakfast with the Experts*
SUNDAY FEBRUARY 28

08h30-10h30

†CAG SYMPOSIUM: Innate Mucosal Immunology

Learning Objectives:
At the end of this session participants will be able to:
1. Describe the role of the inflammasome in gut inflammation.
2. Recognize the contribution of macrophages to innate immune driven inflammation.
3. Explain the role of NOD2 in inflammation and IBD.

Co-Chairs: Samantha Gruenheid, University of British Columbia and Laura Sly, University of British Columbia

- SHIP Regulates IL-1beta Transcription in Macrophages and Intestinal Autoinflammation
  Laura Sly

- Entamoeba histolytica-induced Inflammasome Activation and its Role in Intestinal Pathogenesis
  Kris Chadee, University of Calgary

- Role of ATG16L1 in Bacterial Autophagy - Link with Crohn’s disease
  Dana Philpott, University of Toronto

A multicenter, double-blind, placebo-controlled Phase 3 study of ustekinumab, a human monoclonal antibody to IL-12/23p40, in patients with moderately-severely active Crohn’s disease who are naive or not refractory to anti-TNFα: UNITI-2 (Abstract 24)
  – BG Feagan², C Gasink³, Y Lang³, J Friedman⁴, J Johanss⁵, L Gao⁶, BE Sands¹, S Hanauer⁷, P Rutgeerts⁹, S Targan¹, S Ghosh¹, W de Villiers⁷, JF Colombel¹, Z Tulassay¹, U Seidler¹, W Sandborn⁵
  ¹Mount Sinai Medical Center, New York, New York; ²Robarts Clinical Trials Inc, London, Ontario; ³Northwestern University, Chicago, Illinois; ⁴University of Calgary, Calgary, Alberta; ⁵UCSD, La Jolla, California; ⁶Janssen R & D, LLC, Spring House, Pennsylvania; ⁷University Hospital Gasthuisberg, Leuven, Belgium; ⁸Cedars-Sinai Medical Center, Los Angeles, California; ⁹University of Cape Town, Cape Town, South Africa; ¹⁰Semmelweis University, Budapest, Hungary; ¹¹Hannover Medical School, Hannover, Germany

- Small intestinal bacteria determine gluten metabolism and immunogenicity (Abstract 25)
  – A Caminero Fernandez¹, H Galipeau², J McCarville¹, C Johnston¹, S Bernier¹, A Russell¹, J Casqueiro Blanco¹, J Tye-Din², M Surette¹, N Magarvey¹, E Verdu²
  ¹McMaster University, Hamilton, Ontario; ²Medical Sciences, McMaster University, Hamilton, Ontario; ³Universidad De Leon, Leon, Castilla y Leon, Spain; ⁴The Walter And Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia

09h00-10h30

CAG SYMPOSIUM: Luminal Signaling to Nerves in Functional Disorders: Pathophysiological and clinical implications

Learning Objectives:
At the end of this session participants will be able to:
1. Recognize the relationship between stress, the microbiota, and intestinal inflammation.
2. Describe how luminal factors can modulate sensory nerve signaling from the intestine.
3. Discuss the role of clinical treatments targeting luminal factors in the management of functional bowel disorders.

Co-Chairs: Premysl Berck, McMaster University and Stephen Vanner, Queen’s University

- Interplay of Stress, Gut Microbiota and Inflammation
  Michael Bailey, Ohio State University

- Luminal Signaling to Colonic Afferent Nerves
  David Reed, Queen’s University

- Clinical Treatments Targeting Luminal Signaling in Functional Disorders
  Stephen Vanner

* American College of Gastroenterology Fellow or Master
† Session includes oral presentations of key abstracts
SUNDAY FEBRUARY 28

09h00-10h30  †CASL PAPER SESSION 2  Duluth

Co-Chairs: Alnoor Ramji, University of British Columbia and Hemant Shah, University of Toronto

CASL Student Prize
• Characterization of hepatitis B virus (HBV) lytrotropism and immune status in chronic hepatitis B (CHB) pregnant carriers (Abstract 26)
  – DC Wong, S Gao, S Joshi, T Matwiy, G Samadi Kochaksaarei, G Bindra, G van Marle, SR Martin, E Castillo, CS Coffin
  University of Calgary, Calgary, Alberta

• End-of-life healthcare costs and utilization among patients with end-stage-liver-disease in Ontario: A population-based study (Abstract 27)
  – EM Kelly3, S Murthy3, F Wong1, T Shaw-Stiffel1, L Scully3, M Chalifoux2, P Tanuseputro2, P James3
  1Medicine, Toronto General Hospital, Toronto, Ontario; 2OHRI, Ottawa, Ontario; 3Department of Medicine, The Ottawa Hospital, Ottawa, Ontario

• Protective immunity upon HCV reinfection is associated with selection of memory CD8 T cell clonotypes with the highest functional avidity (Abstract 28)
  – M Boisvert1, MS Abdel-Hakeem1, J Bruneau2, H Soudeyns3, N Shoukry4
  1Centre de recherche du CHUM, 2Centre hospitalier de l’Université de Montréal, and 3Département de microbiologie, infectiologie et immunologie, Université de Montréal – Montréal, Québec

• Developing a prognostic model for significant liver fibrosis in HIV-hepatitis C (HCV) co-infected individuals from the Canadian co-infection cohort study (Abstract 29)
  – N Moqueet1, C Kanagaratham2, D Radzioch3, S Saeed3, RW Platt1, MB Klein4
  2Epidemiology, Biostatistics, and Occupational Health, McGill University, 3Department of Medicine and Department of Human Genetics, McGill University, 4Epidemiology, Biostatistics, and Occupational Health, McGill University, and 5Division of Infectious Diseases and Chronic Viral Illness Service, McGill University Health Centre – Montréal, Québec

• Ornithine phenylacetate attenuates loss of muscle mass and improves hepatic encephalopathy in bile-duct ligated rats (Abstract 30)
  – CR Bosoi2, M Oliveira1, M Clément1, M Tremblay1, G Ten Haeve1, N Deutz3, CF Rose1
  1CRCHUM and 2IRCM, Montréal, Québec; 3Texas A&M University, College Station, Texas

10h30-15h30  ASGE VIDEO CENTRE & EPORTAL CENTRE (See pages 31-32)  Saint-Charles

10h30-11h00  Exhibits and Nutrition Break  Le Grand Salon/Hochelagas 1-3

11h00-11h40  SMALL GROUP SESSIONS (See pages 33-39)  Saint Laurent

SEE: Practical tips (CAG co-developed this program with Olympus Canada to achieve scientific integrity, objectivity and balance)

SEE: Practical tips (CAG co-developed this program with PENTAX Medical to achieve scientific integrity, objectivity and balance)

Exclusive Enteral Nutrition in Pediatrics  Ramezay

Endoscopy in Bariatric Patients  Périconka

Managing Difficult Constipation  Bersimis

Immunization in IBD  Saint Laurent

* American College of Gastroenterology Fellow or Master
† Session includes oral presentations of key abstracts
Patient-centred Care in Endoscopy  Kamouraska 1+2
Bioinformatics and the Microbiome  Youville 1+2
(UAG co-developed this program with Shire Pharma Canada ULC.
 to achieve scientific integrity, objectivity and balance)
Ultrashort Treatments for HCV  Chaudière
(UAG co-developed this program with Merck Canada Inc.
 to achieve scientific integrity, objectivity and balance)
Designing and Delivering Effective Education Sessions  Matapédia
Drug-Induced Liver Injury - Are there any therapies to try?  Harricana

Please note that pre-registration is required to gain admittance to Small Group Sessions.

11h40-11h50  Break
11h50-12h30  SMALL GROUP SESSIONS (See pages 33-39)

SEE: Practical tips  Richelieu
(UAG co-developed this program with Olympus Canada.
 to achieve scientific integrity, objectivity and balance)
Intractable Abdominal Pain in Children - Management options  Ramezay
Is this Food Intolerance or Food Allergy?  Péribonka
Unusual Causes of Abdominal Pain  Bersimis
Arthralgias in IBD  Saint Laurent
(UAG co-developed this program with Merck Canada Inc.
 to achieve scientific integrity, objectivity and balance)
Patient-centred Care in IBD  Kamouraska 1+2
(UAG co-developed this program with Janssen Inc.
 to achieve scientific integrity, objectivity and balance)
Competency by Design/CanMEDS 2015  Youville 1+2
Antibody-Mediated Rejection after Liver Transplant  Chaudière
Pulmonary Complications of Cirrhosis  Matapédia
Can We Ever Stop Nucleoside Analogue Therapy for HBV?  Harricana

Please note that pre-registration is required to gain admittance to Small Group Sessions.

12h30-13h30  Exhibits and Lunch  Le Grand Salon/Hochelagas 1-3
13h30-15h00  CAG SYMPOSIUM
Rapid Fire 2015 Journal Review  Duluth

Learning Objectives:
At the end of this session participants will be:
1. Familiar with many of the highest impact articles in clinical gastroenterology in 2015.
2. Able to decide whether selected publications answer their clinical needs.
3. Able to see if they agree with their peers.

Faculty: Desmond Leddin, Dalhousie University and David Morgan, McMaster University

Use a clicker to vote on multiple-choice questions and test your knowledge of the key papers and findings from 2015!
13h30-15h00  CASL SYMPOSIUM

Hepatocellular Carcinoma (HCC): Controversies in surveillance, diagnosis and management

Learning Objectives:
- At the end of this session participants will be able to:
  1. Analyze the role of alpha-fetoprotein in HCC surveillance.
  2. Identify clinical scenarios where contrast enhanced ultrasound is useful for HCC diagnosis.
  3. Discuss controversies in HCC management in a Canadian context.

Co-Chairs: Kelly Burak, University of Calgary and Kevork Peltekian, Dalhousie University

- Should Alpha-Fetoprotein be used with Ultrasonography for HCC Surveillance?
  Amit Singal, University of Texas Southwestern Medical Centre

- How Can Contrast Enhanced Ultrasound Assist in the Diagnosis of HCC?
  Stephanie Wilson, University of Calgary

- Controversies in Management of HCC (Update from CASL HCC Meeting)
  Kelly Burak

13h30-15h00  CAG RESEARCH AWARD LECTURES

Mackenzie

CAG YOUNG INVESTIGATOR AWARD LECTURE

The Proteomics of Colorectal Cancer: Identification of a protein signature associated with prognosis
François-Michel Boisvert, Université de Sherbrooke
  – Introduction by Nathalie Rivard

CAG RESEARCH EXCELLENCE AWARD LECTURE

Host-Microbe Interactions in the Gut: The epithelium calls the tune!
Bruce Vallance, University of British Columbia
  – Introduction by Deanna Gibson

15h00-15h30  Exhibits and Nutrition Break

Le Grand Salon/Hochelagas 1-3

15h30-17h00  CAG SYMPOSIUM

Duluth

Diarrhea and Constipation: Slow, slow, quick, quick, slow: The colonic tango

Learning Objectives:
- At the end of this session participants will be able to:
  1. Recognize the importance of microbiota in regulation of colonic function and sensation.
  2. Improve their understanding of colonic motility through state-of-the-art diagnostic technology.
  3. Describe the latest technological and pharmacologic treatments for constipation and diarrhea.

Co-Chairs: Christopher Andrews, University of Calgary and Paul Moayyedi*, McMaster University

- What is the Role of Microbiome in Influencing Bowel Habit?
  Premysl Bercik, McMaster University

- Is there a Technological Solution to Constipation?
  Philip Dinning, Flinders University, South Australia

- Pharmacological Options for Chronic Constipation and Diarrhea: Now and in the future
  Christopher Andrews
  – CAG co-developed this program with Allergan Canada to achieve scientific integrity, objectivity and balance –
SUNDAY FEBRUARY 28

15h30-17h00  
**CASL SPECIAL CONFERENCE**

**Saint-Laurent/Gatineau**

**Hepatitis C Virus Update**

**Learning Objectives:**
At the end of this session participants will be able to:
1. Develop an approach to easy and complex HCV treatment scenarios.
2. Evaluate resistance testing and its growing role in management of HCV.
3. Appreciate the technical aspects and challenges of economic analysis for HCV therapies.

Co-Chairs: Curtis Cooper, University of Ottawa and Jordan Feld, University of Toronto

- **Treating HCV is Easy, Except When It Is Hard**
  Alnoor Ramji, University of British Columbia

- **Relevance and Risks of Resistance**
  Richard Harrigan, BC Centre for Excellence in HIV/AIDS

- **The Immunology of the Transition from Acute to Chronic Viral Hepatitis**
  Antonio Bertoletti, Duke-Nus Medical School, Singapore

– CAG co-developed this program with AbbVie to achieve scientific integrity, objectivity and balance –

15h30-17h00  
**†CAG SYMPOSIUM:**

**Mackenzie**

**New Technologies**

**Learning Objectives:**
At the end of this session participants will be able to:
1. Evaluate how novel genomics approaches can be used for drug and biomarker discovery for colorectal cancer.
2. Determine what novel genomic and integrative approaches can be used to identify the key biological pathways that not only explain susceptibility to common diseases but also the basis of disease heterogeneity.
3. Explain how data-dependent and targeted proteomic analyses work, how the results can be integrated with genomic/transcriptomic type data and how proteomics can reveal biological processes that are not accessible by genomic analysis strategies.

Co-Chairs: François-Michel Boisvert, Université de Sherbrooke and Eytan Wine, University of Alberta

- **miR-142-3p and vitamin D-mediated regulation of autophagy: Linking environmental gene interactions in IBD (Abstract 32)**
  – F Dang\textsuperscript{2}, A Hsieh\textsuperscript{2}, I Verpalen\textsuperscript{2}, R Murchie\textsuperscript{2}, LK Greenfield\textsuperscript{2}, M Abdulllah\textsuperscript{2}, D Philpott\textsuperscript{3}, N Jones\textsuperscript{1}
  \textsuperscript{1}The Hospital for Sick Children, Toronto, Ontario; \textsuperscript{2}Cell Biology, The Hospital for Sick Children, Toronto, Ontario; \textsuperscript{3}University of Toronto, Toronto, Ontario

- **High Throughput Genomics in the Search for Novel Therapies and Biomarkers to Advance Management of Colorectal Cancer**
  Isabella Tai, University of British Columbia

- **Going from Genetic Association to a Better Biologic Understanding and Treatment of Inflammatory Bowel Diseases**
  John Rioux, Université de Montréal

- **Proteogenomic Analyses of Colorectal Carcinoma**
  Robbert Slebos, Vanderbilt University Medical School

17h00-18h00  
**2016 CDDW™ AWARDS CEREMONY**

**St. François**

We invite you to join us at the annual Awards Ceremony to congratulate and celebrate with the many awardees as awards from the Associations are formally presented.
18h00-19h30  POSTER SESSION 2  Hochelagas 4-6/Saguenay/Saint Maurice
Join authors and colleagues in relaxed and informative discussions while enjoying beverages and light snacks. Please be sure to see the Posters of Distinction (A193-A197, A208, A214, A229, A230, A247-A253, A315, A331) located throughout the poster area and identified with a ribbon.

20h00-23h30  GALA EVENT  Marquette/Jolliet/Duluth
Centre Ice Gala
Pull on your favourite hockey jersey, and enjoy the company of fellow hockey fans as CDDW™ hosts the “Centre Ice Gala”. Treat your taste buds to the most exotic stadium cuisine, test out your stick handling skills, and skate the night away with tunes from our own Power Play DJ. Purchase tickets ($100 + tax) online and also at registration on-site.
08h00-09h00  CAG BREAKFAST WITH THE EXPERTS  Saint-Maurice

**Difficult Cases in Ulcerative Colitis**

**Learning Objectives:**
At the end of this session participants will be able to:
1. Recognize the need for second-line therapy in acute severe colitis.
2. Assess drug levels and optimize dosing of anti-TNF levels.
3. Identify poor prognostic markers in ulcerative colitis.

Speakers: Marla Dubinsky, Mount Sinai Hospital, New York and Adam Weizman, University of Toronto

Please note that pre-registration is required to gain admittance to Breakfast with the Experts
– CAG co-developed this program with Janssen Inc. to achieve scientific integrity, objectivity and balance –

09h00-10h30  CAG SYMPOSIUM  Duluth

**2015 Papers That Influenced Your Practice**

**Learning Objectives:**
At the end of this session participants will be able to:
1. Consider strategies for implementing therapeutic drug monitoring in IBD management and understand the relationship between biologic drug trough levels and IBD activity.
2. Describe the clinical implications of attempting to treat patients with advanced cirrhosis, including decompensated cirrhosis, with antiviral agents.
3. Recognize the impact of standardized management strategies on IBD outcomes and understand the risk-benefit trade-off of early immunosuppressive therapy for IBD.

Speakers: John Marshall, McMaster University and Eric Yoshida*, University of British Columbia

*The format for this interactive session is that speakers will present three pivotal papers from 2015, providing a 15-minute review of the paper, followed by 10-15 minutes for questions and audience discussion/interaction.*

Papers

  – John Marshall

  – Eric Yoshida*

  – John Marshall

  – CAG co-developed this program with Takeda Canada, Inc. to achieve scientific integrity, objectivity and balance –
MONDAY FEBRUARY 29

09h00-10h30  
**CASL SYMPOSIUM**  
The Future of Hepatology - Diseases and their Cures - Reality or Science Fiction?  
Mackenzie

**Learning Objectives:**
At the end of this session participants will:
1. Recognize how HBV immunology impacts therapeutic choices now and in the future.
2. Appreciate research into liver stem cells and the 3D liver as important to the future of hepatology.
3. Evaluate how curative therapies impact HCC screening in the future.

Co-Chairs: Carla Coffin, University of Calgary and Philip Wong, McGill University

- Age-Dependent Events during HBV Infections: Implications for therapy  
  Antonio Bertoletti, Duke-Nus Medical School, Singapore

- Liver Stem Cells and 3D Artificial Liver  
  Shinichiro Ogawa, University of Toronto

- Future of HCC Screening in the Era of Potent Antivirals for HCV, HBV and the Rise of NASH/NAFLD-related Liver Disease  
  Morris Sherman*, University of Toronto

  – CAG co-developed this program with Gilead Sciences Canada, Inc. to achieve scientific integrity, objectivity and balance –

10h30-11h00  
Nutrition Break  
Foyer

11h00-11h40  
**SMALL GROUP SESSIONS** (See pages 33-39)  
Approach to Uninvestigated Dysphagia  
Saint-Laurent

Case-based Anticoagulation  
Gatineau

Oral Anticoagulants and Cirrhotic Patients – Safety and monitoring  
Bersimis

**Please note that pre-registration is required to gain admittance to Small Group Sessions**

11h40-11h50  
Break

11h50-12h30  
**SMALL GROUP SESSIONS** (See pages 33-39)  
Non-invasive Monitoring of Liver Disease  
Saint-Laurent

(CAG co-developed this program with Merck Canada Inc. to achieve scientific integrity, objectivity and balance)

Managing Chronic Pancreatitis: It's more than just abstinence  
Gatineau

**Please note that pre-registration is required to gain admittance to Small Group Sessions**

12h30-13h30  
Lunch  
Foyer

* American College of Gastroenterology Fellow or Master
CAG SYMPOSIUM
Therapeutics in IBD: Past, present and future

Learning Objectives:
At the end of this session participants will be able to:
1. Identify appropriate (and/or inappropriate) use of steroids and immunosuppressants in the treatment of IBD.
2. Describe optimal use of biologic therapies in the treatment of IBD.
3. Recognize the role of a personalized approach to treatment of IBD.

Co-Chairs: Alain Bitton, McGill University and Sharyle Fowler, University of Saskatchewan

- Should We Still Be Using Steroids and Immunosuppressants to Treat IBD?
  John Marshall, McMaster University

- Current and Upcoming Biologics for Treating IBD
  Subrata Ghosh, University of Calgary

- The Future of IBD Therapy: A personalized approach
  Marla Dubinsky, Mount Sinai Hospital, New York

- CAG co-developed this program with Janssen Inc. to achieve scientific integrity, objectivity and balance –
American Society for Gastrointestinal Endoscopy (ASGE)
Video Centres

At the ASGE Video Centre, located in Saint-Charles, delegates can rotate at their own pace through three video stations which demonstrate endoscopic techniques and technologies. All nine videos are from the ASGE Endoscopic Learning Library collection.

FRIDAY FEBRUARY 26

Station 1 – Radial and Linear EUS
Richard A. Erickson, MD, Brenna C. Bounds, MD, Lawrence Lai, MRCP, William R. Brugge, MD, Mauritz Wiersema, MD, Michael Kochman, MD, Lisa Wiersema, MD
Total run time: 97 minutes

Station 2 – Endoscopic Approach to Hemorrhoids
Rome Jutabha, MD, Tonya Kaltenbach, MD, Roy Soetikno, MD
Total run time: 28 minutes

Station 3 – Diagnostic and Therapeutic Endoscopy in Patients after Ileal Pouch Surgery
Francis A. Farraye, MD, MSc, FASGE, Bo Shen, MD, FASGE
Total run time: 65 minutes

SATURDAY FEBRUARY 27

Station 1 – Biliary Access Techniques for ERCP: From Basic to Advanced
Martin L. Freeman MD; Kapil Gupta, MD, MPH
Total run time: 63 minutes

Station 2 – Small Bowel Imaging
Klaus E. Monkemuller, MD, PhD, FASGE, Marzena Zabielski, RN, BSN, Lucia C. Fry, MD, FASGE, and Helmut Neumann, MD, PhD
Total run time: 40 minutes

Station 3 – Polyposis Syndrome/Genetic GI: Endoscopic Diagnosis and Management
Vinay Chandrasekhara, MD, Anil K. Rustgi, MD, Timothy C. Hoops, MD, Michael L. Kochman, MD, FASGE, Gregory G. Ginsberg, MD, FASGE
Total run time: 60 minutes

SUNDAY FEBRUARY 28

Station 1 – Endoscopic Submucosal Dissection of Colon Lateral Spreading Tumour
Won Young Cho, MD, Bong Min Ko, MD, Gene Hyun Bok, MD, Kwang Yeun Shim, MD, Hyun Gun Kim, PhD, Tae Hee Lee, MD, Suck Ho Lee, MD, So Young Jin, MD, and Joo Young Cho, MD
Total run time: 36 minutes

Station 2 – Endoscopic Interpretation and Therapy of Severe Lower GI Bleeding
Roy Soetikno, MD; Tonya Kaltenbach, MD; Peter Kelsey, MD; Kenneth McQuaid MD, FASGE
Total run time: 33 minutes

Station 3 – EUS-Guided Biliary Drainage: Current Techniques
Vinay Dhir, MD, Takao Itoi, MD, Amit Maydeo, MD
Total run time: 30 minutes

The CAG is grateful to the ASGE for this learning opportunity
Please visit http://www.asge.org/ to order videos

Participants may claim Section 2 Personal Learning Project credits as defined by the Royal College of Physicians and Surgeons of Canada
Visit the ePortal Learning Center in the Saint-Charles Room to Access a Wide Variety of Educational Materials!

The following are just a few of the MANY outstanding videos to choose from:

**from the CDDW™ 2015 Program**

CAG/CASL Postgraduate Course – IBD and Nutrition
- Nutritional Deficiencies in IBD- What is the significance? – Dr. Khursheed Jeejeebhoy
- Nutrition and the Gut Biome-What is the impact in IBD? – Dr. Levinus Dieleman

CAG Symposium – Working with the Bugs
- Not So Unculturable: Recent advances in cultivating the human gut microbiome – Dr. Michael Surette
- Probiotics: Where are we and where are we going?– Dr. Karen Madsen
- Fecal Microbiota Transplant Past, Present and Future – Dr. Christina Surawicz

McKenna Memorial Lecture: Fifty Years of Gastroenterology: a personal reflection- Dr. Don Powell

**from The CAG Basic Science and CanMEDS Lecture Series**

- Dr. Waqqas Afif – Health Advocacy/Choosing Wisely for the IBD Patient – September 2015
- Dr. Louis Liu – Constipation with a Focus on Motility/Anorectal studies – December 2015
- Dr. Hemant Shah – Pre-operative Surgical Risk in Liver Patients – January 2016

**from the 2015 GI Symposium:Microbes, IBD and Other GI Diseases**

- Managing Psychological Aspects of IBD – Dr. Lesley Graff
- Approach to post-operative Crohn’s Disease – Dr. Laura Targownik
- Current Thinking on the Pathogenesis of IBD – Dr. Claudio Fiocchi

Visit the ePortal by logging in to MYCAG

*CAG members* may log in with their member email and password

*CDDW™ participants* may claim Section 2 self-learning credits as defined by the Royal College of Physicians and Surgeons of Canada (RCPSC)

Open:  
- Friday, February 26  09h30-15h00
- Saturday, February 27 10h30-15h30
- Sunday, February 28 10h30-15h30

The CAG is a Recipient of the 2012 Royal College Accredited CPD Provider Innovation Award for the ePortal
**Small Group Sessions**

Small group sessions (limit of up to 35 attendees) are 40-minute interactive, case-based discussions that run from 11h00-11h40 and 11h50-12h30. For room allocations see pages 34-39. **Pre-registration required.**

<table>
<thead>
<tr>
<th>SATURDAY</th>
<th>Saturday 27th</th>
<th>Sunday 28th</th>
<th>Monday 29th</th>
</tr>
</thead>
<tbody>
<tr>
<td>SEE: Practical tips</td>
<td>11h00</td>
<td>11h50</td>
<td></td>
</tr>
<tr>
<td>Investigation of the Small Bowel</td>
<td>🔧</td>
<td>🔧</td>
<td>🔧</td>
</tr>
<tr>
<td>Ultrasound and IBD</td>
<td>🔧</td>
<td>🔧</td>
<td>🔧</td>
</tr>
<tr>
<td>Refractory Encopresis in Pediatrics</td>
<td>🔧</td>
<td>🔧</td>
<td>🔧</td>
</tr>
<tr>
<td>Work-Life Balance Issues</td>
<td>🔧</td>
<td>🔧</td>
<td>🔧</td>
</tr>
<tr>
<td>Interventional EUS</td>
<td>🔧</td>
<td>🔧</td>
<td>🔧</td>
</tr>
<tr>
<td>Infection Models</td>
<td>🔧</td>
<td>🔧</td>
<td>🔧</td>
</tr>
<tr>
<td>Case Discussions in Pediatric Chronic Viral Hepatitis</td>
<td>🔧</td>
<td>🔧</td>
<td>🔧</td>
</tr>
<tr>
<td>Thrombosis and Liver Disease - When to anticoagulate</td>
<td>🔧</td>
<td>🔧</td>
<td>🔧</td>
</tr>
<tr>
<td>HIV and Liver Transplant - Outcomes, barriers and what to expect</td>
<td>🔧</td>
<td>🔧</td>
<td>🔧</td>
</tr>
<tr>
<td>Updates in Fecal Microbiota Transplant</td>
<td>🔧</td>
<td>🔧</td>
<td>🔧</td>
</tr>
<tr>
<td>Colonic Motility</td>
<td>🔧</td>
<td>🔧</td>
<td>🔧</td>
</tr>
<tr>
<td>Early Onset IBD in Pediatrics</td>
<td>🔧</td>
<td>🔧</td>
<td>🔧</td>
</tr>
<tr>
<td>Marijuana and GI Disease</td>
<td>🔧</td>
<td>🔧</td>
<td>🔧</td>
</tr>
<tr>
<td>Colonic Polypectomy</td>
<td>🔧</td>
<td>🔧</td>
<td>🔧</td>
</tr>
<tr>
<td>CDHF Session: Protecting the Human Gut Microbiota to Enhance Health</td>
<td>🔧</td>
<td>🔧</td>
<td>🔧</td>
</tr>
<tr>
<td>Acute on Chronic Liver Failure - When is the patient too sick for transplant?</td>
<td>🔧</td>
<td>🔧</td>
<td>🔧</td>
</tr>
<tr>
<td>Lean NAFLD - Is it different than obese NAFLD?</td>
<td>🔧</td>
<td>🔧</td>
<td>🔧</td>
</tr>
<tr>
<td>Intermediate Stage HCC - What to do?</td>
<td>🔧</td>
<td>🔧</td>
<td>🔧</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SUNDAY</th>
<th>Saturday 27th</th>
<th>Sunday 28th</th>
<th>Monday 29th</th>
</tr>
</thead>
<tbody>
<tr>
<td>SEE: Practical tips</td>
<td>11h00</td>
<td>11h50</td>
<td></td>
</tr>
<tr>
<td>Exclusive Enteral Nutrition in Pediatrics</td>
<td>🔧</td>
<td>🔧</td>
<td>🔧</td>
</tr>
<tr>
<td>Endoscopy in Bariatric Patients</td>
<td>🔧</td>
<td>🔧</td>
<td>🔧</td>
</tr>
<tr>
<td>Managing Difficult Constipation</td>
<td>🔧</td>
<td>🔧</td>
<td>🔧</td>
</tr>
<tr>
<td>Immunization in IBD</td>
<td>🔧</td>
<td>🔧</td>
<td>🔧</td>
</tr>
<tr>
<td>Patient-centred Care in Endoscopy</td>
<td>🔧</td>
<td>🔧</td>
<td>🔧</td>
</tr>
<tr>
<td>Bioinformatics and the Microbiome</td>
<td>🔧</td>
<td>🔧</td>
<td>🔧</td>
</tr>
<tr>
<td>Ultrasart Treatments for HCV</td>
<td>🔧</td>
<td>🔧</td>
<td>🔧</td>
</tr>
<tr>
<td>Designing and Delivering Effective Education Sessions</td>
<td>🔧</td>
<td>🔧</td>
<td>🔧</td>
</tr>
<tr>
<td>Drug-Induced Liver Injury - Are there any therapies to try?</td>
<td>🔧</td>
<td>🔧</td>
<td>🔧</td>
</tr>
<tr>
<td>Intractable Abdominal Pain in Children - Management options</td>
<td>🔧</td>
<td>🔧</td>
<td>🔧</td>
</tr>
<tr>
<td>Is this Food Intolerance or Food Allergy?</td>
<td>🔧</td>
<td>🔧</td>
<td>🔧</td>
</tr>
<tr>
<td>Unusual Causes of Abdominal Pain</td>
<td>🔧</td>
<td>🔧</td>
<td>🔧</td>
</tr>
<tr>
<td>Arthralgias in IBD</td>
<td>🔧</td>
<td>🔧</td>
<td>🔧</td>
</tr>
<tr>
<td>Patient-centred Care in IBD</td>
<td>🔧</td>
<td>🔧</td>
<td>🔧</td>
</tr>
<tr>
<td>Competence by Design/CanMEDS 2015</td>
<td>🔧</td>
<td>🔧</td>
<td>🔧</td>
</tr>
<tr>
<td>Antibody-Mediated Rejection after Liver Transplant</td>
<td>🔧</td>
<td>🔧</td>
<td>🔧</td>
</tr>
<tr>
<td>Pulmonary Complications of Cirrhosis</td>
<td>🔧</td>
<td>🔧</td>
<td>🔧</td>
</tr>
<tr>
<td>Can We Ever Stop Nucleoside Analogue Therapy for HBV?</td>
<td>🔧</td>
<td>🔧</td>
<td>🔧</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MONDAY</th>
<th>Saturday 27th</th>
<th>Sunday 28th</th>
<th>Monday 29th</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approach to Uninvestigated Dysphagia</td>
<td>🔧</td>
<td>🔧</td>
<td>🔧</td>
</tr>
<tr>
<td>Case-based Anticoagulation</td>
<td>🔧</td>
<td>🔧</td>
<td>🔧</td>
</tr>
<tr>
<td>Oral Anticoagulants and Cirrhotic Patients - Safety and monitoring</td>
<td>🔧</td>
<td>🔧</td>
<td>🔧</td>
</tr>
<tr>
<td>Non-invasive Monitoring of Liver Disease</td>
<td>🔧</td>
<td>🔧</td>
<td>🔧</td>
</tr>
<tr>
<td>Managing Chronic Pancreatitis: It's more than just abstinence</td>
<td>🔧</td>
<td>🔧</td>
<td>🔧</td>
</tr>
</tbody>
</table>
Small Group Sessions

Small group sessions are interactive, case-based discussions that run from 11h00-11h40 and 11h50-12h30. **Pre-registration required.**

- **SEE: Practical tips** **Saturday and Sunday, February 27 & 28, 11h00 & 11h50 (Richelieu)**
  **Learning Objectives:** 1) Demonstrate how scope handling influences colonoscopy technique, 2) Demonstrate how to apply torque steering during colonoscopy, 3) Demonstrate how to integrate changes in handling and torque into one’s colonoscopy technique.
  **Speakers:** Lawrence Hookey, Queen’s University and Alaa Rostom, University of Ottawa (Saturday 11h00); Frances Tse, McMaster University and Kevin Waschke, McGill University (Saturday 11h50); Eric Greenwald, McMaster University and Donald MacIntosh, Dalhousie University (Sunday 11h00); Mark Borgaonkar*, Memorial University and Alaa Rostom, University of Ottawa (Sunday 11h50)
  CAG co-developed this program with Olympus Canada to achieve scientific integrity, objectivity and balance

- **SEE: Practical tips** **Saturday and Sunday, February 27 & 28, 11h00 (Gatineau)**
  **Learning Objectives:** 1) Demonstrate how scope handling influences colonoscopy technique, 2) Demonstrate how to apply torque steering during colonoscopy, 3) Demonstrate how to integrate changes in handling and torque into one’s colonoscopy technique.
  **Speakers:** David Armstrong*, McMaster University and Dana Farina, Dalhousie University (Saturday); Frances Tse, McMaster University and Kevin Waschke, McGill University (Sunday)
  CAG co-developed this program with PENTAX Medical to achieve scientific integrity, objectivity and balance

- **Investigation of the Small Bowel** **Saturday, February 27, 11h00 (Bersimis)**
  **Learning Objectives:** 1) Understand key conditions that result in obscure GI bleeding, 2) Identify which instruments are ideal to investigate the small bowel and 3) Recognize limitations – advantages and disadvantages – of various instruments for small bowel evaluation.
  **Speakers:** Robert Enns, University of British Columbia and Christopher Teshima, University of Toronto
  CAG co-developed this program with Olympus Canada to achieve scientific integrity, objectivity and balance

- **Ultrasound and IBD** **Saturday, February 27, 11h00 (Saint-Laurent)**
  **Learning Objectives:** 1) Understand the pros/cons of different imaging modalities available today for both diagnosis and monitoring of patients with IBD, 2) Recognize four key sonographic components of active IBD, review a simple score for disease activity (Simple Ultrasonographic Score/SUS) and identify complications of IBD on bowel ultrasound, 3) Understand how ultrasound may be used in clinical decision-making, and 4) Recognize how ultrasound can be used in the future as a clinical tool to differentiate between IBS and IBD in patients referred for symptoms such as diarrhea.
  **Speakers:** Cathy Lu, University of Alberta and Kerri Novak, University of Calgary
  CAG co-developed this program with Merck Canada Inc. to achieve scientific integrity, objectivity and balance

- **Refractory Encopresis in Pediatrics** **Saturday, February 27, 11h00 (Kamouraska 1+2)**
  **Learning Objectives:** 1) Identify the difference between retentive and non-retentive fecal incontinence in children, 2) Describe the initial steps in management of a child with fecal incontinence, 3) Assess the need for additional investigations and referral to other allied health members in children with refractory fecal incontinence, and 4) Recognize the global impact of refractory fecal incontinence on the child and family’s quality of life.
  **Speakers:** Dominique Levesque, McGill University and Alfred Yeung, University of Calgary

- **Work-Life Balance Issues** **Saturday, February 27, 11h00 (Ramezay)**
  **Learning Objectives:** 1) Identify work-life balance issues present in the practice of gastroenterology/medicine, 2) Describe features of physician burnout, 3) Identify issues within the healthcare system that contribute to work-life imbalance, and 4) Describe resources/strategies available to decrease burnout and improve balance and resilience.
  **Speakers:** Melanie Beaton, Western University and Lana Bistritz, University of Alberta

- **Interventional EUS** **Saturday, February 27, 11h00 (Péribonka)**
  **Learning Objectives:** 1) Review the indications, efficacy and techniques of EUS-guided celiac plexus block and neurolysis, 2) Discuss the evidence and technical advances in EUS-guided pancreatic fluid collection drainage, 3) Comment on the role of EUS-guided fiducial placement in radiation therapy, and 4) Identify the indications and risks associated with EUS bilio-pancreatic access and drainage.
  **Speakers:** Charles Ménard, Université de Sherbrooke and Frances Tse, McMaster University
  CAG co-developed this program with Olympus Canada to achieve scientific integrity, objectivity and balance

---

Small Group Sessions are interactive, case-based discussions that run from 11h00-11h40 and 11h50-12h30. Pre-registration required.
Small Group Sessions Continued

Small group sessions are interactive, case-based discussions that run from 11h00-11h40 and 11h50-12h30. Pre-registration required.

- **Infection Models**
  
  **Learning Objectives:** 1) Describe the various infection models used in IBD research, 2) Recognize the strengths and limitations of each of the models, and 3) Identify areas for further innovation and development.

  **Speakers:** Brian Coombes, McMaster University and Deanna Gibson, University of British Columbia

- **Case Discussions in Pediatric Chronic Viral Hepatitis**

  **Learning Objectives:** 1) Discuss common viral hepatitis scenarios in the pediatric population, and 2) Identify how new therapies for viral hepatitis could be applied to the pediatric population.

  **Speakers:** Simon Ling, University of Toronto and Steven Martin, University of Calgary

  CAG co-developed this program with Merck Canada Inc. to achieve scientific integrity, objectivity and balance

- **Thrombosis and Liver Disease - When to anticoagulate**

  **Learning Objectives:** 1) Appreciate both the anticoagulant and procoagulant factors that can be abnormal in patients with cirrhosis, and 2) Develop an approach to the management and choice of anticoagulants for thrombotic conditions in cirrhotic patients including portal vein thrombosis, deep vein thrombosis, and pulmonary embolism.

  **Speakers:** Aman Arya, University of Toronto and Jennifer Flemming, Queen's University

- **HIV and Liver Transplant - Outcomes, barriers and what to expect**

  **Learning Objective:** Be aware of the indications and outcomes of liver transplantation in HIV positive recipients.

  **Speakers:** Eberhard Renner, University of Toronto and Eric Yoshida*, University of British Columbia

- **Updates in Fecal Microbiota Transplant**

  **Learning Objectives:** 1) Describe current pediatric and adult evidence for fecal microbial transplantation (FMT) in the management of recurrent *Clostridium difficile* infection, 2) Discuss current pediatric and adult evidence for the role of FMT in the management of Crohn's disease and ulcerative colitis, 3) Assess patient eligibility for FMT and identify potential risks, and 4) Describe Health Canada regulations concerning FMT.

  **Speakers:** Dina Kao, University of Alberta and Nikhil Pai, McMaster University

- **Colonic Motility**

  **Learning Objectives:** 1) Recognize common patterns of colonic motility, 2) Identify indications for colonic manometry studies in children, adolescents and adults, and 3) Evaluate the pros and cons of different motor function tests currently employed.

  **Speakers:** Jan Huizinga, McMaster University and Elyanne Ratcliffe, McMaster University

- **Early Onset IBD in Pediatrics**

  **Learning Objectives:** 1) Describe current experience with potential therapeutic options for children with primary anti-TNF failure, 2) Recognize limitations of current diagnostic modalities, and 3) Identify children who would benefit from first-line biological therapeutics.

  **Speakers:** David Mack, University of Ottawa and Anthony Otley, Dalhousie University

  CAG co-developed this program with Janssen Inc. to achieve scientific integrity, objectivity and balance

- **Marijuana and GI Disease**

  **Learning Objectives:** 1) Recognize the prevalence and patterns of use of cannabis by patients with GI diseases, 2) Assess the evidence base for cannabinoid use in GI disorders, and 3) Discuss the barriers and facilitators for authorizing the clinical use of cannabinoids in GI disease.

  **Speakers:** Constantine Soulellis, McGill University and Mark Ware, McGill University
Small Group Sessions Continued

Small group sessions are interactive, case-based discussions that run from 11h00-11h40 and 11h50-12h30. Pre-registration required.

- **Colonic Polypectomy** Saturday, February 27, 11h50 (Péribonka)
  Learning Objectives: 1) Describe morphological assessment of polyps according to the Paris Classification, 2) Assess laterally spreading polyps for safe and efficient endoscopic mucosal resection (EMR), 3) Identify critical aspects of EMR technique, and 4) Recognize and manage EMR-related complications.
  Speakers: Paul Kortan*, University of Toronto and Donald MacIntosh, Dalhousie University
  CAG co-developed this program with PENTAX Medical to achieve scientific integrity, objectivity and balance

- **CDHF Session: Protecting the Human Gut Microbiota to Enhance Health** Saturday, February 27, 11h50 (Youville 1+2)
  Learning Objectives: 1) Explain how the human gut microbiota impacts digestive and overall health, and 2) Recognize risk factors that may negatively impact a healthy gut microbiota.
  Speakers: David Armstrong*, McMaster University and Richard Hunt*, Canadian Digestive Health Foundation
  CAG co-developed this program with Shire Pharma Canada ULC to achieve scientific integrity, objectivity and balance

- **Acute on Chronic Liver Failure - When is the patient too sick for transplant?** Saturday, February 27, 11h50 (Chaudière)
  Learning Objectives: 1) Define acute on chronic liver failure, 2) Establish a prognosis, and 3) Determine transplant candidacy.
  Speakers: Vince Bain, University of Alberta and Paul Marotta, Western University

- **Lean NAFLD - Is it different than obese NAFLD?** Saturday, February 27, 11h50 (Matapédia)
  Learning Objectives: 1) Describe the different risk factors for development of NASH in the lean adult population, and understand how this may be a different pathophyslogic mechanism than obese NASH, 2) Be able to have a treatment algorithm for management of patients with lean NASH, 3) Understand which children with NAFLD actually have ‘lean NAFLD’, and 4) Be able to diagnose and treat patients with lean NAFLD secondary to syndromes or other conditions that affect lipid metabolism.
  Speakers: Saumya Jayakumar, University of Calgary and Marialena Mouzaki, University of Toronto

- **Intermediate Stage HCC - What to do?** Saturday, February 27, 11h50 (Hariciana)
  Learning Objectives: 1) Recognize intermediate stage HCC, 2) Understand the research behind the recommended treatments, and 3) Identify what treatments are not optimal.
  Speakers: Kelly Burak, University of Calgary and Morris Sherman*, University of Toronto

- **Exclusive Enteral Nutrition in Pediatrics** Sunday, February 28, 11h00 (Ramezay)
  Learning Objectives: 1) Recognize the unique features and advantages of exclusive enteral nutrition (EEN) in treating patients with pediatric IBD, 2) Describe potential mechanisms of action of EEN, 3) Discuss novel future variations on nutritional therapy and potential applications to understanding IBD pathogenesis and treatment, and 4) Identify the crucial role of allied health professionals in successful implementation of an enteral nutrition program.
  Speakers: Anthony Otley, Dalhousie University and Eytan Wine, University of Alberta

- **Endoscopy in Bariatric Patients** Sunday, February 28, 11h00 (Péribonka)
  Learning Objectives: 1) Define the role of surgery in the morbidly obese patient and understand the different surgical treatment options, 2) Appreciate the clinical outcomes of bariatric surgery and clarify the frequency and severity of complications, and 3) Discuss the indications for endoscopy in bariatric surgical patients and evaluate novel endoscopic strategies for management of morbid obesity.
  Speakers: Rajesh Aggarwal, McGill University and Gary May, University of Toronto
  CAG co-developed this program with PENTAX Medical to achieve scientific integrity, objectivity and balance

- **Managing Difficult Constipation** Sunday, February 28, 11h00 (Bersimis)
  Learning Objectives: 1) Describe the evidence for current therapies for constipation in pediatric and adult populations, and 2) Understand the differences in evaluation of constipation between children, adolescents, and adults.
  Speakers: Christopher Andrews, University of Calgary and Eylanne Ratcliffe, McMaster University
Small Group Sessions Continued

Small group sessions are interactive, case-based discussions that run from 11h00-11h40 and 11h50-12h30. **Pre-registration required.**

- **Immunization in IBD**
  Sunday, February 28, 11h00 (Saint-Laurent)
  Learning Objectives: 1) Describe timing of immunizations in IBD patients, 2) Explain the implications of live vaccines to IBD patients, and 3) Identify patients at risk of preventable infections.
  Speakers: Marla Dubinsky, Mount Sinai Hospital New York and Sophie Plamondon, Université de Sherbrooke
  CAG co-developed this program with Merck Canada Inc. to achieve scientific integrity, objectivity and balance

- **Patient-centred Care in Endoscopy**
  Sunday, February 28, 11h00 (Kamouraska 1+2)
  Learning Objectives: 1) Reflect upon one's own practice using the dimensions of patient-centred care, 2) Be able to discuss the pros and cons of current quality indicators, 3) Initiate a patient-centred quality endoscopy process at one's institution/practice, 4) Challenge oneself to examine something one thinks he/she already knows, and 5) Examine the factors one would use to choose the endoscopist for their own colonoscopy.
  Speakers: Catherine Dubé, University of Ottawa and Roger Hollingworth, Credit Valley Hospital

- **Bioinformatics and the Microbiome**
  Sunday, February 28, 11h00 (Youville 1+2)
  Learning Objectives: 1) Identify the processes used to convert raw sequence reads into preliminary microbiome analyses, 2) Critically make decisions about steps that will impact the analyses, and 3) Describe the utility of a few different downstream analysis tools.
  Speaker: Jennifer Stearns, McMaster University
  CAG co-developed this program with Shire Pharma Canada ULC to achieve scientific integrity, objectivity and balance

- **Ultrashort Treatments for HCV**
  Sunday, February 28, 11h00 (Chaudière)
  Learning Objectives: 1) Discuss the patient characteristics that would be considered for a short course of therapy, and 2) Explore future potential ‘ultra-short’ regimens for HCV.
  Speakers: Jordan Feld, University of Toronto and Alnoor Ramji, University of British Columbia
  CAG co-developed this program with Merck Canada Inc. to achieve scientific integrity, objectivity and balance

- **Designing and Delivering Effective Education Sessions**
  Sunday, February 28, 11h00 (Matapédia)
  Learning Objectives: 1) Identify the principles and factors that contribute to effective adult learning, 2) Develop an approach to the design of effective education sessions, and 3) Appreciate the factors that contribute to effective delivery of education sessions.
  Speakers: Catharine Walsh, University of Toronto and Winnie Wong, University of Alberta

- **Drug Induced Liver Injury - Are there any therapies to try?**
  Sunday, February 28, 11h00 (Harricana)
  Learning Objective: Review the clinical approach and management strategies for drug-induced liver injury.
  Speakers: Constantine Karvellas, University of Alberta

- **Intractable Abdominal Pain in Children - Management options**
  Sunday, February 28, 11h50 (Ramezay)
  Learning Objectives: 1) Define intractable abdominal pain within the context of a bio-psychosocial model of care, 2) Identify diagnostic strategies for the detection of subtle intestinal inflammatory disease, 3) Recognize the importance of peripheral and central sensitization to the development of chronic pain, and 4) Assess the need for pharmacological and non-pharmacological interventions in conjunction with the pain-service and clinical psychology.
  Speakers: Kevan Jacobson, University of British Columbia and Angela Noble, Queen's University

- **Is this Food Intolerance or Food Allergy?**
  Sunday, February 28, 11h50 (Péribonka)
  Learning Objectives: 1) Describe the tests available to diagnose a food allergy, 2) Discuss the limitations associated with commonly used diagnostic tests for food allergy, and 3) Discuss the clinical application of the low FODMAP diet in patients with suspected food intolerances and IBS.
  Speakers: Peter Gibson, Monash University and Maitreyi Raman, University of Calgary
Small Group Sessions Continued

Small group sessions are interactive, case-based discussions that run from 11h00-11h40 and 11h50-12h30. Pre-registration required.

- **Unusual Causes of Abdominal Pain**
  - **Learning Objectives:** Have: 1) An approach to managing patients with chronic abdominal pain, 2) An appreciation of some common causes of neuropathic pain in the abdomen, and 3) An understanding of appropriate strategies for an effective referral to a physical therapist.
  - **Speakers:** David Armstrong*, McMaster University and Shanker Nesathurai, McMaster University
  - **Sunday, February 28, 11h50 (Bersimis)**

- **Arthralgias in IBD**
  - **Learning Objectives:** 1) Identify different presentations of arthritis in the IBD patient, 2) Develop an understanding and working knowledge of treatment strategies to address the many facets of disease in this patient population, and 3) Optimize cross-specialty referrals.
  - **Speakers:** Talat Bessissow, McGill University and Elizabeth Hazel, McGill University
  - **Sunday, February 28, 11h50 (Saint-Laurent)**

- **Patient-centred Care in IBD**
  - **Learning Objectives:** 1) Explore the determinants of patient-centred care in IBD, 2) Identify obstacles to patient-centred care for IBD patients in the physician's own clinical environment, and 3) Determine strategies to promote patient-centred care in the management of IBD patients.
  - **Speakers:** Alain Bitton, McGill University and Sylviane Forget, McGill University
  - **Sunday, February 28, 11h50 (Kamouraska 1+2)**

- **Competency by Design/CanMEDS 2015**
  - **Learning Objectives:** 1) Explain the key components for competence by design for residency education programs, 2) Discuss how milestones and entrustable professional activities will serve to promote learning and assessment across the CanMEDS Roles, and 3) Describe the strategies and tools to support program directors and clinical supervisors prior to and during the transition to competence by design.
  - **Speaker:** Craig Campbell, Royal College of Physicians and Surgeons of Canada
  - **Sunday, February 28, 11h50 (Youville 1+2)**

- **Antibody-Mediated Rejection after Liver Transplant**
  - **Learning Objective:** Review our evolving understanding of antibody-mediated rejection and its impact on post-transplant management.
  - **Speakers:** Stephen Congly, University of Calgary and Aldo Montano-Loza, University of Alberta
  - **Sunday, February 28, 11h50 (Chaudière)**

- **Pulmonary Complications of Cirrhosis**
  - **Learning Objectives:** 1) Recognize who needs screening, and how to make the diagnosis, for portopulmonary hypertension and hepatopulmonary syndrome, and know the highlights of management and prognosis, and 2) Describe management options for the challenging clinical problem of hepatic hydrothorax.
  - **Speakers:** Jennifer Leonard, Memorial University and Puneeta Tandon, University of Alberta
  - **Sunday, February 28, 11h50 (Matapédia)**

- **Can We Ever Stop Nucleoside Analogue Therapy for HBV?**
  - **Learning Objectives:** 1) Discuss the clinical/laboratory variables that indicate a successful course of therapy, and 2) Identify the laboratory test results associated with a long-term quiescent phase of HBV infection.
  - **Speakers:** Carla Coffin, University of Calgary and David Wong, University of Toronto
  - **Sunday, February 28, 11h50 (Haricanna)**

- **Approach to Uninvestigated Dysphagia**
  - **Learning Objectives:** 1) Describe an approach to evaluate patients presenting with dysphagia, and 2) Recognize the role of upper GI barium study, endoscopy, and esophageal manometry to assess patients with dysphagia.
  - **Speaker:** Louis Liu, University of Toronto
  - **Monday, February 29, 11h00 (Saint-Laurent)**

- **Case-based Anticoagulation**
  - **Learning Objectives:** 1) Understand the bleeding risks related to endoscopic procedures, 2) Utilize an evidence-based approach to evaluating a patient's risk of thrombotic events, and 3) Be familiar with the indications for bridging of anticoagulation around endoscopic procedures.
  - **Speakers:** Vicky Tagalakis, McGill University and Kevin Waschke, McGill University
  - **Monday, February 29, 11h00 (Gatineau)**
Small Group Sessions Continued

Small group sessions are interactive, case-based discussions that run from 11h00-11h40 and 11h50-12h30. Pre-registration required.

- **Oral Anticoagulants and Cirrhotic Patients - Safety and monitoring**  Monday, February 29, 11h00 (Bersimis)
  Learning Objective: Develop an approach to the use of oral anticoagulants in cirrhotic patients.
  Speakers: Meredith Borman, University of Calgary and Carla Coffin, University of Calgary

- **Non-invasive Monitoring of Liver Disease**  Monday, February 29, 11h50 (Saint-Laurent)
  Learning Objectives: 1) Recognize the clinical importance of staging fibrosis for management and prognosis in chronic liver diseases, 2) Identify and describe the different non-invasive modalities to diagnose and monitor liver disease, and 3) Compare and contrast the benefits and limitations of the non-invasive monitoring modalities, such as Fibroscan, Fibrotest, Fib-4 and APRI.
  Speakers: Hin Hin Ko, University of British Columbia and Giada Sebastiani, McGill University
  CAG co-developed this program with Merck Canada Inc. to achieve scientific integrity, objectivity and balance

- **Managing Chronic Pancreatitis: It’s more than just abstinence**  Monday, February 29, 11h50 (Gatineau)
  Learning Objective: 1) Discuss the medical management of chronic pancreatitis, 2) Evaluate the data on celiac plexus block in the management of chronic pancreatitis, 3) Identify which patients to refer for endoscopic management, and 4) Recognize which patients to refer for surgical management.
  Speakers: Michael Cantor, University of Manitoba and Jennifer Telford*, University of British Columbia

CDDW™ 2017
Banff, February 26 – March 8
**SUMMARY OF ROYAL COLLEGE OF PHYSICIANS AND SURGEONS OF CANADA ACCREDITED SECTION 1 CREDITS**

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Credits</th>
<th>Session Title</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Friday, February 26</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08h00-09h30</td>
<td>1.5</td>
<td>CAG/CASL Postgraduate Course: Community-based GI and Liver Disease</td>
<td></td>
</tr>
<tr>
<td>09h00-09h30</td>
<td>1.5</td>
<td>IBD Microbiota</td>
<td></td>
</tr>
<tr>
<td>10h00-11h30</td>
<td>1.5</td>
<td>CAG/CASL Postgraduate Course: Inpatient Hepatology</td>
<td></td>
</tr>
<tr>
<td>10h00-11h30</td>
<td>1.5</td>
<td>CAG Selected Clinical Presentations</td>
<td></td>
</tr>
<tr>
<td>10h00-11h30</td>
<td>1.5</td>
<td>CAG/CCC Student Prize Paper Presentations</td>
<td></td>
</tr>
<tr>
<td>12h30-14h30</td>
<td>2</td>
<td>CAG/CASL Postgraduate Course: Safety Monitoring</td>
<td></td>
</tr>
<tr>
<td>12h30-14h30</td>
<td>2</td>
<td>Cellular Reprogramming in GI Diseases</td>
<td></td>
</tr>
<tr>
<td>15h00-16h30</td>
<td>1.5</td>
<td>CAG/CASL Postgraduate Course: Video Endoscopy</td>
<td></td>
</tr>
<tr>
<td>15h00-16h30</td>
<td>1.5</td>
<td>Colonic Motility</td>
<td></td>
</tr>
<tr>
<td><strong>Saturday, February 27</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08h00-09h00</td>
<td>1</td>
<td>Breakfast with the Experts: Celiac Disease: Case based</td>
<td></td>
</tr>
<tr>
<td>08h00-09h00</td>
<td>1</td>
<td>Breakfast with the Experts: Barrett's Esophagus</td>
<td></td>
</tr>
<tr>
<td>08h00-09h00</td>
<td>1</td>
<td>Breakfast with the Experts: Difficult AILD Cases</td>
<td></td>
</tr>
<tr>
<td>08h00-10h00</td>
<td>2</td>
<td>Epigenetics of Gastrointestinal Cancer</td>
<td></td>
</tr>
<tr>
<td>08h30-10h00</td>
<td>1.5</td>
<td>CASL Paper Session 1</td>
<td></td>
</tr>
<tr>
<td>09h00-10h00</td>
<td>1</td>
<td>Precision Medicine as an Emerging Theme in Gastroenterology</td>
<td></td>
</tr>
<tr>
<td>10h00-10h30</td>
<td>0.5</td>
<td>CLF-CASL Gold Medal Lecture</td>
<td></td>
</tr>
<tr>
<td>11h00-11h40</td>
<td>0.75</td>
<td>Small Group Sessions</td>
<td></td>
</tr>
<tr>
<td>11h50-12h30</td>
<td>0.75</td>
<td>Small Group Sessions</td>
<td></td>
</tr>
<tr>
<td>13h30-15h00</td>
<td>1.5</td>
<td>The Role of Nutrition in Gastroenterology</td>
<td></td>
</tr>
<tr>
<td>13h30-15h00</td>
<td>1.5</td>
<td>Updates in Pediatric Cholestasis</td>
<td></td>
</tr>
<tr>
<td>13h30-15h00</td>
<td>1.5</td>
<td>Research Career Development</td>
<td></td>
</tr>
<tr>
<td>15h30-16h30</td>
<td>1</td>
<td>Kopelman Lecture</td>
<td></td>
</tr>
<tr>
<td>15h30-17h00</td>
<td>1.5</td>
<td>Monitoring Disease Activity in IBD</td>
<td></td>
</tr>
<tr>
<td>15h30-17h00</td>
<td>1.5</td>
<td>Optimizing Fatty Liver Outcomes</td>
<td></td>
</tr>
<tr>
<td>17h30-18h30</td>
<td>1</td>
<td>McKenna Lecture</td>
<td></td>
</tr>
<tr>
<td><strong>Sunday, February 28</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08h00-09h00</td>
<td>1</td>
<td>Breakfast with the Experts: Difficult Cases in Crohn's Disease</td>
<td></td>
</tr>
<tr>
<td>08h00-09h00</td>
<td>1</td>
<td>Breakfast with the Experts: Advances in H. pylori Therapeutics</td>
<td></td>
</tr>
<tr>
<td>08h00-09h00</td>
<td>1</td>
<td>Breakfast with the Experts: HRS and SBP: Tips and tricks</td>
<td></td>
</tr>
<tr>
<td>08h30-10h30</td>
<td>2</td>
<td>Innate Mucosal Immunology</td>
<td></td>
</tr>
<tr>
<td>09h00-10h30</td>
<td>1.5</td>
<td>Luminal Signaling to Nerves in Functional Disorders: Pathophysiological and clinical implications</td>
<td></td>
</tr>
<tr>
<td>09h00-10h30</td>
<td>1.5</td>
<td>CASL Paper Session 2</td>
<td></td>
</tr>
<tr>
<td>11h00-11h40</td>
<td>0.75</td>
<td>Small Group Sessions</td>
<td></td>
</tr>
<tr>
<td>11h50-12h30</td>
<td>0.75</td>
<td>Small Group Sessions</td>
<td></td>
</tr>
<tr>
<td>13h30-15h00</td>
<td>1.5</td>
<td>Rapid Fire 2015 Journal Review</td>
<td></td>
</tr>
<tr>
<td>13h30-15h00</td>
<td>1.5</td>
<td>HCC: Controversies in surveillance, diagnosis and management</td>
<td></td>
</tr>
<tr>
<td>13h30-15h00</td>
<td>1.5</td>
<td>CAG Young Investigator and Research Excellence Lectures</td>
<td></td>
</tr>
<tr>
<td>15h30-17h00</td>
<td>1.5</td>
<td>Diarrhea and Constipation: Slow, slow, quick, quick, slow: The colonic tango</td>
<td></td>
</tr>
<tr>
<td>15h30-17h00</td>
<td>1.5</td>
<td>New Technologies</td>
<td></td>
</tr>
<tr>
<td>15h30-17h00</td>
<td>1.5</td>
<td>HCV Update</td>
<td></td>
</tr>
<tr>
<td><strong>Monday, February 29</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08h00-09h00</td>
<td>1</td>
<td>Breakfast with the Experts: Difficult Cases in Ulcerative Colitis</td>
<td></td>
</tr>
<tr>
<td>09h00-10h30</td>
<td>1.5</td>
<td>2015 Papers that Influenced your Practice</td>
<td></td>
</tr>
<tr>
<td>09h00-10h30</td>
<td>1.5</td>
<td>The Future of Hepatology - Diseases and their Cures - Reality or Science Fiction?</td>
<td></td>
</tr>
<tr>
<td>11h00-11h40</td>
<td>0.75</td>
<td>Small Group Sessions</td>
<td></td>
</tr>
<tr>
<td>11h50-12h30</td>
<td>0.75</td>
<td>Small Group Sessions</td>
<td></td>
</tr>
<tr>
<td>13h30-15h00</td>
<td>1.5</td>
<td>Therapeutics in IBD: Past, present and future</td>
<td></td>
</tr>
</tbody>
</table>

This educational program offers a total of 90.75 hours of Section 1 accredited learning and up to 28.5 credits per delegate. Please visit http://www.cag-acg.org/ to evaluate the conference and print your certificate.
Fairmont Queen Elizabeth
Floor Plans
### EXHIBITORS

<table>
<thead>
<tr>
<th>Company: AbbVie</th>
<th>Address: 8401 Trans-Canada Highway Saint-Laurent, QC H4S 1Z1</th>
<th>Contact: Chantal Neron</th>
<th>Telephone: 514-941-1982</th>
<th>Email: <a href="mailto:chantal.neron@abbvie.com">chantal.neron@abbvie.com</a></th>
<th>Booth Number: 1022</th>
</tr>
</thead>
<tbody>
<tr>
<td>AbbVie is a global, research-based biopharmaceutical company that combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases. The company has several core areas of focus, including gastroenterology and hepatitis C. AbbVie aims to help patients live healthier lives and collaborate on sustainable healthcare solutions. For further information, please visit <a href="http://www.abbvie.ca">www.abbvie.ca</a>.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Company: AFFINITY Diagnostics Corp.</th>
<th>Address: 194 Wildcat Road Toronto, ON M3J 2N5</th>
<th>Contact: Daniel Libertucci</th>
<th>Telephone: 416-650-6300</th>
<th>Email: <a href="mailto:info@affinitydiagnostics.ca">info@affinitydiagnostics.ca</a></th>
<th>Booth Number: 1037</th>
</tr>
</thead>
<tbody>
<tr>
<td>AFFINITY Diagnostics Corp. is provider of high quality in-vitro diagnostic assays for clinical and research laboratory use. Our featured product for CDDW 2016 is the IDK® CALPROTECTIN ELISA. Fecal Calprotectin is a marker for inflammatory and neoplastic gastrointestinal diseases. The IDK® Calprotectin ELISA enables the differential diagnosis between Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD). Calprotectin is also an ideal marker for therapy monitoring in IBD patients. At AFFINITY our commitment to providing quality in our products and excellence in our service is the backbone of our business, and the strength of our organization.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Company: Allergan Canada</th>
<th>Address: 85 Enterprise Blvd. Suite 500 Markham, ON L6G 0B5</th>
<th>Contact: Customer Service</th>
<th>Telephone: 855-892-8766</th>
<th>Email: <a href="mailto:canadainfo@actavis.com">canadainfo@actavis.com</a></th>
<th>Booth Number: 1027</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allergan markets a portfolio of best-in-class products that provide valuable treatments for gastroenterology, the central nervous system, eye care, medical aesthetics, women’s health, urology, cardiovascular and anti-infective therapeutic categories, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Company: ALPCO</th>
<th>Address: 26-G Keewaydin Drive Salem, NH 03079</th>
<th>Contact: Jennifer Mayes</th>
<th>Telephone: 800-592-5726</th>
<th>Email: <a href="mailto:jmayes@alpco.com">jmayes@alpco.com</a></th>
<th>Booth Number: 1043</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALPCO offers a wide range of testing solutions, providing scientists and healthcare professionals with vital tools for advancing research and improving quality of care. Our product portfolio includes applications for immunoassays, HPLC, LC-MS/MS, purified antibodies, recombinant proteins, and our new STELLUX® chemiluminescent assay platform.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Company: BioScript Solutions</th>
<th>Address: 77 Vaughan Harvey Blvd Moncton, NB E1C 0K2</th>
<th>Contact: Marla Pisegna</th>
<th>Telephone: 506-260-4224</th>
<th>Email: <a href="mailto:mpisegna@bioscript.ca">mpisegna@bioscript.ca</a></th>
<th>Booth Number: 1038</th>
</tr>
</thead>
<tbody>
<tr>
<td>BioScript is Centred Around You BioScript is wholly focused on biologic and specialty pharmaceuticals, providing knowledgeable, trustworthy support to doctors and patients managing complex, chronic illnesses. We strive to be true clinical partners, helping achieve the best possible results from prescribed therapies. BioScript is independent and Canadian-owned, with locations in every province. We’re the only pharmacy wholly focused on specialty pharmaceuticals with nationwide coverage, allowing us to support you—whether prescriber or patient—wherever you are.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Company: Boston Scientific Ltd.</th>
<th>Address: 6430 Vipond Drive Mississauga, ON L5T 1W8</th>
<th>Contact: Kristin Muzylko</th>
<th>Telephone: 905-696-1947</th>
<th>Email: <a href="mailto:kristin.muzylko@bsci.com">kristin.muzylko@bsci.com</a></th>
<th>Booth Number: 1013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 30 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Company:</td>
<td>Bristol-Myers Squibb Canada</td>
<td>Company:</td>
<td>Canadian Digestive Health Foundation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------</td>
<td>-----------------------------</td>
<td>---------</td>
<td>-------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td>2344 Alfred-Nobel, Suite 300</td>
<td>Address:</td>
<td>2525 Old Bronte Road, Suite 455</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Montréal, QC H4S 0A4</td>
<td></td>
<td>Oakville, ON L6M 4J2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact:</td>
<td>Richard Arlen</td>
<td>Contact:</td>
<td>Catherine Mulvale</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Email:</td>
<td><a href="mailto:richard.arlen@bms.com">richard.arlen@bms.com</a></td>
<td>Email:</td>
<td><a href="mailto:Director@CDHF.ca">Director@CDHF.ca</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Booth Number:</td>
<td>1036, 1045</td>
<td>Booth Location:</td>
<td>2001</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Bristol-Myers Squibb Canada is an indirect wholly-owned subsidiary of Bristol-Myers Squibb Company, a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Bristol-Myers Squibb Canada est une filiale indirecte détenue en propriété exclusive de Bristol-Myers Squibb, une société biopharmaceutique d’envergure mondiale dont la mission est de découvrir, mettre au point et fournir des médicaments novateurs ayant pour but d’aider les patients à combattre des maladies graves.

<table>
<thead>
<tr>
<th>Company:</th>
<th>BÜHLMANN</th>
<th>Company:</th>
<th>Canadian Liver Foundation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Address:</td>
<td>105 Route 101A</td>
<td>Address:</td>
<td>3100 Steeles Avenue East, Suite 801</td>
</tr>
<tr>
<td></td>
<td>Amherst, NH 03031</td>
<td></td>
<td>Markham, ON L3R 8T3</td>
</tr>
<tr>
<td>Contact:</td>
<td>Collin Shaw</td>
<td>Contact:</td>
<td>Gary A. Fagan</td>
</tr>
<tr>
<td>Telephone:</td>
<td>603-731-1756</td>
<td>Telephone:</td>
<td>800-563-5483</td>
</tr>
<tr>
<td>Email:</td>
<td><a href="mailto:cms@buhlmannlabs.com">cms@buhlmannlabs.com</a></td>
<td>Email:</td>
<td><a href="mailto:gfagan@liver.ca">gfagan@liver.ca</a></td>
</tr>
<tr>
<td>Booth Number:</td>
<td>1050</td>
<td>Booth Location:</td>
<td>2002</td>
</tr>
</tbody>
</table>

BÜHLMANN has developed into THE CALPROTECTIN COMPANY with highest quality standards and its determination to increase the knowledge and application of fecal calprotectin (fCAL). BÜHLMANN Diagnostics Corp is now the exclusive North American affiliate for BÜHLMANN Laboratories in Switzerland, offering the BÜHLMANN fCAL® ELISA, BÜHLMANN fCAL® turbo, Quantum Blue® Calprotectin Rapid Test and IBDoc® smartphone for at home testing.

<table>
<thead>
<tr>
<th>Company:</th>
<th>Canadian Association of Gastroenterology</th>
<th>Company:</th>
<th>Cedarlane Laboratories Ltd.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Address:</td>
<td>1540 Cornwall Road, Suite 224</td>
<td>Address:</td>
<td>4410 Paletta Court</td>
</tr>
<tr>
<td></td>
<td>Oakville, ON L6J 7W5</td>
<td></td>
<td>Burlington, ON L7L 5R2</td>
</tr>
<tr>
<td>Contact:</td>
<td>Paul Sinclair</td>
<td>Contact:</td>
<td>Jessica Johnston</td>
</tr>
<tr>
<td>Telephone:</td>
<td>888-780-0007</td>
<td>Telephone:</td>
<td>800-268-5058 or 289-288-0001</td>
</tr>
<tr>
<td>Email:</td>
<td></td>
<td>Email:</td>
<td><a href="mailto:jessica.johnston@cedarlanelabs.com">jessica.johnston@cedarlanelabs.com</a></td>
</tr>
<tr>
<td>Booth Number:</td>
<td>2004, 2008</td>
<td>Booth Number:</td>
<td>1028</td>
</tr>
</tbody>
</table>

Over 1100 members including gastroenterologists, surgeons, pediatricians, radiologists and basic scientists comprise the CAG. CAG members are actively involved in research, education and patient care in all areas of digestive health and disease, contributing to the economic and social health of all Canadians.

We are CAG’s Foundation. Established in 1993, the Canadian Digestive Foundation supports patients, gastroenterologists and investigators to help reduce suffering and improve quality of life for those impacted by digestive disease. Patients, and the health care professionals who care for them, know they can rely on the CDHF to provide accurate, unbiased, patient-friendly resources. CAG members trust their foundation to heighten public awareness and fund important research, training and knowledge translation activities. We exist to benefit you, your patients and your research. Get to know your foundation today. Visit us at CDDW and www.CDHF.ca.

The Canadian Liver Foundation (CLF) is a national charity committed to promoting liver health and reducing unnecessary death and suffering from liver disease. The CLF has contributed nearly $25 million to liver research in Canada and through its chapters across the country, the CLF strives to promote liver health, improve public awareness and understanding of liver disease, raise funds for research and provide support to individuals affected by liver disease. To learn more about how the CLF is “Bringing Liver Research to Life”, visit LIVER.ca.

CEDARLANE® (www.cedarlanelabs.com) (ISO 13485) is a 100% Canadian owned company specializing in providing high quality reagents. CEDARLANE® provides clinicians with licensed diagnostic products including BioHit’s Biopsy Quick Tests for H. pylori and Lactose Intolerance, and the NEW Liver and Gastro Line Immuno Assays (UA) from Human GmbH. We offer one of the most extensive product listings in Canada (>1400 suppliers), allowing our customers the opportunity to ‘Consolidate & Save’. 
### EXHIBITORS

<table>
<thead>
<tr>
<th>Company: Cook Medical</th>
<th>Company: Endosoft, Utech Products</th>
</tr>
</thead>
<tbody>
<tr>
<td>Address: 165 Mostar Street</td>
<td>135 Broadway</td>
</tr>
<tr>
<td>Contact: Tony Ranucci</td>
<td>Schenectady, NY 12305</td>
</tr>
<tr>
<td>Telephone: 905-640-7110 ext. 108174</td>
<td>Contact: Ashley Cipriano</td>
</tr>
<tr>
<td>Email: <a href="mailto:tony.ranucci@cookmedical.com">tony.ranucci@cookmedical.com</a></td>
<td>Telephone: 518-831-8095</td>
</tr>
<tr>
<td>Booth Number: 1007</td>
<td>Email: <a href="mailto:acipriano@endosoft.com">acipriano@endosoft.com</a></td>
</tr>
<tr>
<td></td>
<td>Booth Number: 1029</td>
</tr>
</tbody>
</table>

Since 1963, Cook Group companies develop healthcare devices. We are at the forefront of medical research and product development in minimally invasive medical device technology for diagnostic and therapeutic procedures. Depuis 1963, les sociétés du Groupe Cook effectuent le développement des dispositifs médicaux. Nous sommes au premier rang de la recherche médicale et du développement des produits et de la technologie des dispositifs médicaux à effraction minimale aux fins des interventions diagnostiques et thérapeutiques.

<table>
<thead>
<tr>
<th>Company: Crohn’s and Colitis Canada</th>
<th>Company: Ferring Pharmaceuticals</th>
</tr>
</thead>
<tbody>
<tr>
<td>Address: 60 St. Clair Avenue East, Suite 600</td>
<td>200 Yorkland Boulevard, Suite 500</td>
</tr>
<tr>
<td>Contact: Helen Silbiger</td>
<td>North York, ON M2J 5C1</td>
</tr>
<tr>
<td>Telephone: 416-920-5035</td>
<td>Contact: General Inquiries</td>
</tr>
<tr>
<td>Email: <a href="mailto:HSilbiger@crohnsandcolitis.ca">HSilbiger@crohnsandcolitis.ca</a></td>
<td>Telephone: 416-490-0121 or 800-263-4057</td>
</tr>
<tr>
<td>Booth Number: 2009</td>
<td>Email: <a href="mailto:medicalinformation@ferring.com">medicalinformation@ferring.com</a></td>
</tr>
</tbody>
</table>

Crohn’s and Colitis Canada is the only national, volunteer-based charity focused on finding the cures for Crohn’s disease and ulcerative colitis and improving the lives of children and adults affected by these diseases. We are one of the top two health charity funders of Crohn’s and colitis research in the world, investing over $94 million in research to date. We are transforming the lives of people affected by Crohn’s and colitis (the two main forms of inflammatory bowel disease) through research, patient programs, advocacy, and awareness.

<table>
<thead>
<tr>
<th>Company: EndoChoice</th>
<th>Company: Gastrointestinal Society</th>
</tr>
</thead>
<tbody>
<tr>
<td>Address: 11810 Wills Road</td>
<td>231-3665 Kingsway Society</td>
</tr>
<tr>
<td>Contact: George Cronin</td>
<td>Vancouver, BC V5R 5W2</td>
</tr>
<tr>
<td>Telephone: 888-682-3636</td>
<td>Contact: Gail Attara</td>
</tr>
<tr>
<td>Email: <a href="mailto:george.cronin@endochoice.com">george.cronin@endochoice.com</a></td>
<td>Telephone: 866-600-4875</td>
</tr>
<tr>
<td>Booth Number: 1053</td>
<td>Email: <a href="mailto:gail@badgut.org">gail@badgut.org</a></td>
</tr>
<tr>
<td></td>
<td>Booth Number: 2003</td>
</tr>
</tbody>
</table>

EndoSoft offers specialty specific procedure documentation, practice management, image management, Electronic Health Record (EHR), E - Prescriptions and PACS. With these best-of-breed applications and over 25,000 clinical users worldwide, EndoSoft has achieved a leadership position and a reputation for excellence and quality.

Ferring Pharmaceuticals is a research-driven specialty biopharmaceutical company who identifies, develops and markets innovative products not only in Gastroenterology but in a number of key therapeutic areas. We believe in the power of people and research - and go where ideas and research take us. Ferring operates in 60 countries, markets its products in 110 countries and employs more than 5000 employees. The Ferring Philosophy: “People Come First at Ferring” means more than just five simple words. To us, it is a guiding principle that inspires everything we do - from our business practices to our relationships with patients and physicians.

We are committed to improving the lives of individuals with gastrointestinal and liver conditions by supporting research, advocating for appropriate patient access to health care, and promoting gastrointestinal and liver health. Physicians order ~550,000 of our free patient information pamphlets annually. Our popular websites, badgut.org and mauxdeventre.org draw 750,000+ unique visitors annually. They contain up-to-date information in many formats (text, videos, infographics). We hold free BadGut® Lectures for patients from coast-to-coast-to-coast on a variety of GI and liver topics. Subscription to our quarterly Inside Tract® | Du Cœur au ventreMC newsletter is just $20 annually.
EXHIBITORS

Company: Gilead Sciences Canada Inc.
Address: 600-6711 Mississauga Road
Mississauga, ON L5N 2W3
Contact: Shannon Ambeau
Telephone: 416-528-1279
Email: Shannon.Ambeau@gilead.com
Booth Number: 1021

About Gilead Sciences: Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California. Gilead Sciences Canada, Inc. is the Canadian affiliate of Gilead Sciences, Inc. and was established in Mississauga, Ontario in 2005.

Company: Innomar Strategies
Address: 3470 Superior Court
Oakville, ON L6L 0C4
Contact: Jessica Lovett
Telephone: 905-847-4310
Email: jlovett@innomar-strategies.com
Booth Number: 1009

Innomar Strategies, a part of AmerisourceBergen, is the leading patient support provider in the Canadian specialty biopharmaceutical market. We deliver end-to-end commercialization solutions to improve product access, increase supply chain efficiency and enhance patient care. Our integrated solutions include: Consulting Services, Patient Support Programs, Nursing and Clinical Services and Specialty Pharmacy and Logistics. We partner closely with manufacturers, healthcare providers, pharmacies and payers to ensure patients have consistent and reliable access to specialty medication. With our integrated approach and commitment to best-in-class care, Innomar Strategies helps navigate the patient journey to optimize health outcomes. Visit us at www.innomar-strategies.com.

Company: Janssen Inc.
Address: 19 Green Belt Drive
Toronto, ON M3C 1L9
Contact: Frankie Tai
Telephone: 800-387-8781 ext. 3911
Email: ftai@its.jnj.com
Booth Number: 1026

Janssen Inc. is one of the Janssen Pharmaceutical Companies of Johnson & Johnson, which are dedicated to addressing and solving some of the most important unmet medical needs in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases.

Company: Laborie
Address: 6415 Northwest Drive, Unit 11
Mississauga, ON L4V 1X1
Contact: Christine Frewen
Telephone: 888-522-6743
Email: cfrewen@laborie.com
Booth Number: 1039

LABORIE, the global leader in pelvic health diagnostics, brings freedom and dignity to patients suffering from pelvic floor disorders through innovation in diagnostic and treatment options. LABORIE’s product line includes solutions for Urodynamics, Anorectal Manometry, Uroflowmetry, Clinical Informatics, Ultrasound and Pelvic Floor Rehabilitation.

Company: LifeLabs
Address: 100 International Blvd.
Toronto, ON M9W 6J6
Contact: Stephanie Sayer
Telephone: 877-849-3637
Email: stephanie.sayer@lifelabs.com
Booth Number: 1052

LifeLabs is a Canadian-owned company with over 50 years of experience providing laboratory testing services to help healthcare providers diagnose, treat, monitor and prevent disease in patients. In communities across British Columbia and Ontario, LifeLabs’ delivers cost-effective, convenient access to laboratory testing services which are essential for optimal outcomes in healthcare. LifeLabs employs approximately 5,400 professionally trained staff and delivers over 100 million laboratory tests, serving 19 million patient visits annually. LifeLabs is indirectly owned by OMERS Administration Corporation, whose interest is managed by Borealis Infrastructure. For information, visit www.lifelabs.com.

Company: KNS Canada Inc.
Address: 2020 Ellesmere Road, Units 12-13
Toronto, ON M1H 2Z8
Contact: Tania Batista
Telephone: 800-233-1008
Email: tania@knscanada.com
Booth Number: 1051

KNS Canada is a leading provider of novel medical devices and solutions for Hepatology and Gastroenterology. Our signature products include FibroScan non-invasive liver diagnostic device to detect and quantify Liver Stiffness and thereby Liver Fibrosis and Controlled Attenuation Parameter and thereby Steatosis. The portable FibroScan 402 version now is available with XL probe required for obese patients. KNS has launched two new products in 2015: FibroMeter, a blood marker to quantify stages of Fibrosis and inflammation and a non-invasive breath test for the detection of H Pylori Bacteria. Please visit us at booth 1051 or www.knscanada.com.

Company: LifeLabs
Address: 100 International Blvd.
Toronto, ON M9W 6J6
Contact: Stephanie Sayer
Telephone: 877-849-3637
Email: stephanie.sayer@lifelabs.com
Booth Number: 1052

LifeLabs is a Canadian-owned company with over 50 years of experience providing laboratory testing services to help healthcare providers diagnose, treat, monitor and prevent disease in patients. In communities across British Columbia and Ontario, LifeLabs’ delivers cost-effective, convenient access to laboratory testing services which are essential for optimal outcomes in healthcare. LifeLabs employs approximately 5,400 professionally trained staff and delivers over 100 million laboratory tests, serving 19 million patient visits annually. LifeLabs is indirectly owned by OMERS Administration Corporation, whose interest is managed by Borealis Infrastructure. For information, visit www.lifelabs.com.
### Lupin Pharma Canada Ltd.

**Address:** 1155 boul. Rene-Levesque Ouest, #2500
Montreal, QC H3B 2K4

**Contact:** Patrick Nadeau
**Telephone:** 514-866-3863
**Email:** pnadeau@lupin-canada.com

**Booth Number:** 1030

Lupin Pharma Canada is a subsidiary of Lupin, a pharmaceutical company committed to providing world-class medications. Founded in 1968, the company is named after the Lupin flower and shares the same inherent qualities of strength, determination and nurturing. Lupin, the 3rd largest Indian pharmaceutical company, and the 6th largest pharmaceutical company in the US by number of prescriptions, was established in Canada in 2014. Lupin is focused on addressing unmet medical needs in gastroenterology by providing the medical community with Zaxine (rifaximin) to manage patients with hepatic encephalopathy by reducing their risk of recurrence.

### Medtronic

**Address:** 8455 Trans-Canada
St-Laurent, QC H4S 1Z1

**Contact:** Andrew Thomson
**Telephone:** 514-258-4800
**Email:** andrew.thomson@medtronic.com

**Booth Number:** 1015

As a global leader in medical technology, services and solutions, Medtronic helps to improve the lives and health of millions of people each year. We use our deep clinical, therapeutic, and economic expertise to address the complex challenges faced by healthcare systems today. Let's take healthcare Further, Together.

### Merck Canada Inc.

**Address:** 16750 Trans Canada Highway
Kirkland, QC H9H 4M7

**Contact:** Customer Service
**Telephone:** 800-567-2954
**Email:** info@merck.com

**Booth Number:** 1024

Today's Merck is a global healthcare leader working to help the world be well. For more information about our operations in Canada. La société Merck d’aujourd’hui est un chef de file mondial dans le domaine des soins de santé qui vise à aider le monde à vivre mieux. Pour de plus amples renseignements à propos de nos activités au Canada.

### Mylan EPD

**Address:** 85 Advance Road
Etobicoke, ON M8Z 2S6

**Contacts:** Prashanth Dinavahi & Lea Michaels-Khan
**Telephone:** 416-207-1626
**Email:** prashanth.dinavahi@mylan.com

**Booth Number:** 1048

Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we offer a growing portfolio of around 1,400 generic pharmaceuticals and several brand medications. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in about 145 countries and territories. Our workforce of approximately 30,000 people is dedicated to creating better health for a better world, one person at a time.

### Nestlé Nutrition

**Address:** 25 Sheppard Avenue West
North York, ON M2N 6S8

**Contact:** Wallace Leung
**Telephone:** 800-565-1871

**Booth Number:** 1008

Nestlé Health Science is a health-science company engaged in advancing the role of nutritional therapy to change the course of health for consumers, patients and our partners in healthcare. In Canada, the portfolio of nutrition solutions and devices target a number of health areas including pediatrics, acute care, long-term-care, obesity care, healthy aging and gastrointestinal health. Through investing in innovation and leveraging leading edge science, we bring forward innovative nutritional therapies with proven clinical, health economic value and quality of life benefits.

### Odan

**Address:** 3255 Stillview Avenue
Pointe Claire, QC H9R 2Y6

**Contact:** Customer Service
**Telephone:** 514-428-1628
**Email:** info@odanlab.com

**Booth Number:** 1003

Odan Laboratories Ltd. is a privately held Canadian pharmaceutical company which develops, manufactures and markets pharmaceutical specialties and generic health care products. Established in 1974, Odan is focused on providing quality medicines at affordable prices to consumers while addressing the professional needs of pharmacists, physicians and health care professionals. Odan offers a broad line of innovative and generic products covering more than 20 different therapeutic categories. These include gout therapy, endotracheal non aerosol anesthetics, topical anesthetics, hematimics, cholesterol lowering medication, iron deficiency treatment, corneal edema relief, vitamins, antibiotic preparations, gastrointestinal products (purgatives, stool softeners, and anorectal therapies) and dermatological treatments for dermatoses, diabetic skin conditions, psoriasis, seborrhea and xerosis.
## EXHIBITORS

### Olympus Canada
- **Company**: Olympus Canada  
- **Address**: 25 Leek Crescent, Richmond Hill, ON L4B 4B3  
- **Contact**: Andrew McKenzie  
- **Telephone**: 289-269-0285  
- **Email**: andrew.mckenzie@olympus.com  
- **Booth Number**: 1004, 1023

Olympus develops leading edge technology for healthcare professionals that help improve outcomes and enhance quality of life for patients. At CDDW, Olympus will exhibit the new EVIS EXERA III true High Definition series video platform featuring, HDTV, Dual Focus, NBI, Responsive Insertion Technology, also a full line of EndoTherapy accessories and the exclusive ScopeGuide technology that provides a real-time 3D image of the colon. Olympus offers the first universal endoscopic ultrasound processor to combine electronic and mechanical scanning for both exclusive gastrointestinal and pulmonary diseases in a single device. Olympus will also be showing information for interested physicians in Private Endoscopy Clinics offering information on products and services available as a clinic goes through the set-up process.

### Ovesco Endoscopy
- **Company**: Ovesco Endoscopy  
- **Address**: 120 Quade Drive, Cary, NC 27513  
- **Contact**: James Potts  
- **Telephone**: 985-944-2515  
- **Email**: jbpotts@aol.com  
- **Booth Number**: 1041

Ovesco Endoscopy USA is a medical device company specializing in the fields of flexible endoscopy and endoluminal surgery. Ovesco develops, manufactures, and markets innovative products for the treatment of gastrointestinal disease. Ovesco products stand for therapeutic efficacy and efficient application.

### Pendopharm, Pharmascience
- **Company**: Pendopharm, Pharmascience  
- **Address**: 6111 Royalmount Avenue, Montréal, QC H4P 2T4  
- **Contact**: Michael Shaw  
- **Telephone**: 514-340-9800  
- **Email**: mshaw@pendopharm.com  
- **Booth Number**: 1018

PENDOPHARM is a rapidly growing, independent business that focuses on commercializing a portfolio of specialty prescription products and an established line of OTC/BTC products. Strategically committed to growth, PENDOPHARM is actively engaged in licensing, developing and marketing late-stage prescription products as well as consumer brands.

### Pentax Medical
- **Company**: PENTAX Medical  
- **Address**: 6715 Millcreek Drive, Unit 1, Mississauga, ON L5N 5V2  
- **Contact**: Susan Brinker  
- **Telephone**: 905-286-5570  
- **Email**: brinker@pentaxmedical.com  
- **Booth Number**: 1020

PENTAX Medical is a trusted partner who provides quality endoscopic products and services in a cost-effective manner. Through leading-edge R&D and manufacturing, we develop innovative HD endoscopy imaging platforms and productivity software technologies for diagnostic, therapeutic and research applications for Gastroenterology, Pulmonary, and Endoscopic Ultrasound.

### Procter & Gamble
- **Company**: Procter & Gamble  
- **Address**: 4711 Yonge Street, Toronto, ON M2N 6K8  
- **Contact**: Katy Klosowski  
- **Telephone**: 416-730-5904  
- **Email**: klosowski.k@pg.com  
- **Booth Number**: 1010

P&G is a proud supporter of the Canadian Association of Gastroenterology. At P&G, we understand our responsibility is to work together with the leaders who define our healthcare landscape. Our association with the CAG drives us to consistently aim at improving the lives of Canadians with our range of personal health care products including Align and Metamucil. P&G Personal Health Care, proudly supporting and recognizing the leadership of the Canadian Association of Gastroenterology.

### Shire Pharma Canada ULC
- **Company**: Shire Pharma Canada ULC  
- **Address**: 2250 Alfred-Nobel Blvd., Suite 500, Ville St-Laurent, QC H4S 2C9  
- **Contact**: Brigitte Viel  
- **Telephone**: 514-787-5114  
- **Email**: bviel@shire.com  
- **Booth Number**: 1032 (Hereditary Angioedema) 1033 (Gastrointestinal) 1035 (Short Bowel Syndrome)

Shire enables people with life-altering conditions to lead better lives. Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs. The Shire Canadian head office is located in Saint-Laurent (Montréal), Québec, where we focus on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine. We are proud to support Canadian healthcare professionals involved in the treatment of ulcerative colitis, among others, and initiatives meant to enable patients to lead better lives.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Address:</td>
<td>9220 – 25 Avenue</td>
<td>Address:</td>
<td>435 North Service Road West, 1st Floor</td>
</tr>
<tr>
<td></td>
<td>Edmonton, AB T6N 1E1</td>
<td></td>
<td>Oakville, ON L6M 4X8</td>
</tr>
<tr>
<td>Contact:</td>
<td>Jaylene Lavoie</td>
<td>Contact:</td>
<td>Rose Guthrie</td>
</tr>
<tr>
<td>Telephone:</td>
<td>800-661-9993</td>
<td>Telephone:</td>
<td>905-469-4913</td>
</tr>
<tr>
<td>Email:</td>
<td><a href="mailto:jaylene.lavoie@somagen.com">jaylene.lavoie@somagen.com</a></td>
<td>Email:</td>
<td><a href="mailto:roselia.guthrie@takeda.com">roselia.guthrie@takeda.com</a></td>
</tr>
<tr>
<td>Booth Number:</td>
<td><strong>1012</strong></td>
<td>Booth Number:</td>
<td><strong>1025</strong></td>
</tr>
</tbody>
</table>

As Canada’s leading laboratory diagnostics distribution company, we represent an expanding portfolio of innovative products and technologies for autoimmunity and inflammatory diseases.

<table>
<thead>
<tr>
<th>Company:</th>
<th>Stanton Territorial Health Authority</th>
<th>Company:</th>
<th>Tilray</th>
</tr>
</thead>
<tbody>
<tr>
<td>Address:</td>
<td>PO Box 10, Yellowknife</td>
<td>Address:</td>
<td>1100 Maughan Road</td>
</tr>
<tr>
<td></td>
<td>Yellowknife, NT X1A 2N1</td>
<td></td>
<td>Nanaimo, BC V9X 1J2</td>
</tr>
<tr>
<td>Contact:</td>
<td>Cammy Mailloux</td>
<td>Contact:</td>
<td>Jade Pover</td>
</tr>
<tr>
<td>Telephone:</td>
<td>867-669-4379 or 866-389-3149</td>
<td>Telephone:</td>
<td>250-722-3991</td>
</tr>
<tr>
<td>Email:</td>
<td><a href="mailto:cammy_mailloux@gov.nt.ca">cammy_mailloux@gov.nt.ca</a></td>
<td>Email:</td>
<td><a href="mailto:jade.pover@tilray.ca">jade.pover@tilray.ca</a></td>
</tr>
<tr>
<td>Booth Number:</td>
<td><strong>1006</strong></td>
<td>Booth Number:</td>
<td><strong>1042</strong></td>
</tr>
</tbody>
</table>

Our specialists, based in Yellowknife’s 100-bed hospital, provide services with an integrated team of healthcare providers, to the whole of the NWT and parts of Western Nunavut – a population of about 50,000. In-house services include: Ophthalmology; Otolaryngology; Orthopedics; Internal Medicine; Pediatrics; General Surgery; Obstetrics and Gynecology; Psychiatry; Radiology and Public Health, with visiting specialists in Oncology; Gyn Oncology; Neurology; Nephrology; Rheumatology; Urology; Orthopedics – Backs and Pediatric; Pediatric - Cardiology, Psychiatry and Allergy. We offer generous salaries and benefits - call, callback, travel clinic stipends; substantial vacation and CME; recruitment and retention bonuses. Come – the North will give you its best perspective, untamed beauty and a community of lifelong friends.

<table>
<thead>
<tr>
<th>Company:</th>
<th>SuperSonic Imagine</th>
<th>Company:</th>
<th>Vantage Endoscopy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Address:</td>
<td>206 Joseph-Carrier</td>
<td>Address:</td>
<td>90 Gough Road, Unit 1</td>
</tr>
<tr>
<td></td>
<td>Vaudreuil-Dorion, QC J7V 5V5</td>
<td></td>
<td>Markham, ON L3R 5V5</td>
</tr>
<tr>
<td>Contact:</td>
<td>Yves Pâquet</td>
<td>Contact:</td>
<td>Jeff Fynn</td>
</tr>
<tr>
<td>Telephone:</td>
<td>450-510-1595 or 866-904-6246</td>
<td>Telephone:</td>
<td>647-233-9997</td>
</tr>
<tr>
<td>Email:</td>
<td><a href="mailto:yves@apexiummed.com">yves@apexiummed.com</a></td>
<td>Email:</td>
<td><a href="mailto:jeff@vantageendoscopy.com">jeff@vantageendoscopy.com</a></td>
</tr>
<tr>
<td>Booth Number:</td>
<td><strong>1044</strong></td>
<td>Booth Number:</td>
<td><strong>1016</strong></td>
</tr>
</tbody>
</table>

SuperSonic Imagine is an innovative ultrasound imaging company that has developed a revolutionary ultrasound system: the Aixplorer®. Aixplorer is the only system on the market with an UltraFast™ Imaging platform that insures impeccable image quality and real time ShearWave™ Elastography (SWE™). FDA Cleared SWE measures shear wave velocity in tissue. Aixplorer's ShearWave Elastography mode is used worldwide to non-invasively visualize and quantitatively measure (in kilopascals) tissue liver stiffness across the different stages of fibrosis leading up to cirrhosis.

Better Health, Brighter Future - It seems like a simple goal, but it can be a complex task. Our way to better health is by advancing science to develop new medicines to meet the needs of Canadians. Takeda has been developing health solutions for more than 230 years as Japan’s leading pharmaceutical company. Canadians have benefited from Takeda science for many years through our partnerships. Now we are bringing our health solutions directly to you as Takeda Canada. We continue our promise to finding and developing new innovations, because our goal for your better health has many stages, but no end.

Tilray is a Licensed Producer of medical cannabis committed to working with Canadian patients and Health Canada to produce exceptional strains that adhere to the Marihuana for Medical Purposes Regulations. Tilray strives to improve scientific understanding of the therapeutic potential of cannabis. To assist the medical community, we have developed continuing education programs for health care practitioners, and are national leaders in medical cannabis research. Secure and discreet delivery within 24 hours to most areas across Canada. Tilray.ca.

Vantage Endoscopy has developed relationships with many of the world's premier manufacturers that focus on the needs of the physicians, nursing staff and infection control practitioners who make a difference in the diagnosis and treatment of Gastrointestinal disease. Our ambition is to provide leadership and support in selecting and operating the products that best serve medical staff and their patients.
Registration is required to attend this symposium – Limited space available 250 seats

5th Canadian Symposium on HCV / 5ième Symposium canadien sur le VHC

Theme “We’re not Done Yet: Remaining Challenges in Hepatitis C”

February 26, 2016 / 26 février 2016

Fairmont The Queen Elizabeth Hotel, Montréal, QC

Salon St. François

Program – Programme

07h15 - 08h00
Registration, Breakfast, Exhibition and Poster Area Opens – Inscription, déjeuner et ouverture de la salle des affiches

08h00 - 08h15
Welcome and Introductions – Mot de bienvenue
Dr. Naglaa Shoukry, Université de Montréal, Montréal, Canada

Biomedical Sciences
Co-Chairs: Dr. Hugo Soudeyns and Dr. Sonya MacParland

08:15 - 08h45
Opening Keynote: How Close Are we to Realizing an HCV Vaccine?
Dr. Andrea Cox, Johns Hopkins University, Baltimore, USA

08h45 - 09h05
Is it Time to Move on from HCV? A Basic Science Perspective
Dr. Daniel Lamarre, Université de Montréal, Montréal, Canada

Oral Presentations – Présentations orales

09h05 - 09h15
Transcriptomic Characterization of the Immune Response to Acute Hepatitis C Virus Infection
Dr. Naglaa Shoukry, Université de Montréal, Montréal, Canada

09h15 - 09h25
Investigating the Mechanisms of Action of Neutralizing Antibody Responses Elicited by a Recombinant Hepatitis C Virus Envelope Glycoprotein E1E2 Vaccine
Jason A. Wong, University of Alberta, Edmonton, Canada

Clinical Sciences
Co-Chairs: Dr. Marc Bilodeau and Dr. Lisa Barrett

09h25 - 09h55
Targeting HCV: What Have we Learned from Real World Roll Out of DAAs?
Dr. David Nelson, University of Florida, Gainesville, USA

09h55 - 10h10
Coffee Break – Pause café

10h10 - 10h30
Will HCV Antiviral Resistance Matter?
Dr. Richard Harrigan, University of British Columbia, Vancouver, Canada

Oral Presentations - Présentations orales

10h30 - 10h40
Real Life Clinical Experience with Second Generation Directly Acting Antiviral (DAA) Drugs for the Treatment of Chronic Hepatitis C in Calgary, Alberta, Canada
Dr. Golasa Samadi Kochaksaraei, University of Calgary, Calgary, Canada

10h40 - 10h50
Real Life Experience of Hepatitis C Management with Interferon-Free DAA Treatments in Montreal
Dr. Emmanuelle Huchet, Clinique Médicale l’Actuel, Montréal, Canada

Epidemiology and Public Health
Co-Chairs: Dr. Julie Bruneau and Sahar Saeed

10h50 - 11h20
HCV Prevention: Modeling the Impact of Expanding HCV Treatment
Dr. Matthew Hickman, University of Bristol, Bristol, UK

11h20 - 11h40
Harm Reduction Along the HCV Prevention and Care Continuum
Dr. Joseph Cox, McGill University Health Centre, Montréal, Canada
Oral Presentations - Présentations orales

11h40 - 11h50  Correctional Facilities As HCV Treatment Access Point: a Framework for Corrections Research and HCV Treatment
Dr. Lisa Barrett, Dalhousie University, Halifax, Canada

11h50 - 12h00  Risk of Hepatitis C Virus Re-Infection or Late Relapse after Sustained Virologic Response to Interferon-based Therapy in HIV Co-infected Canadians
Carmine Rossi, McGill University, Montréal, Canada

12h00 - 13h15  Lunch – Diner: Saint-Laurent and Gatineau, Convention Floor

Behavioural Sciences
Co-Chairs: Dr. Benedikt Fischer and Emmanuel Fortier

13h15 - 13h45  Challenges in Implementing HCV Therapy Broadly in Low and Middle Income Countries
Dr. Manal El-Sayed, Ain Shams University, Cairo, Egypt

13h45 - 14h05  How Indigenous Methodologies can Inform our Response to the HCV Epidemic in Canada
Renée Masching, Canadian Aboriginal AIDS Network, Dartmouth, Canada

14h05 - 14h15  Community-Directed Research Priorities for Those with Indigenous Lived Hepatitis C Experience
Chris Macklin, Simon Fraser University, Coquitlam, Canada

14h15 - 14h25  CACTUS Montreal: Initiatives to Identify Needs of PWID to Provide a Support and Increase Their Hep C Treatment Access
Julie Bouchard, CACTUS Montréal, Montréal, Canada

14h25 - 14h40  Coffee Break – Pause café

14h40 - 14h50  The Evolving Role of Nurses in the Hepatitis C Care
Geri Hirsch, Nova Scotia Health Authority, Halifax, Canada

14h50 - 15h00  Patient Advocate

15h00 - 15h40  Debate: ‘Is an HCV Vaccine Really Needed?’
Pro: Dr. Andrea Cox, Johns Hopkins University, Baltimore, USA
Con: Dr. David Wong, University Health Network, Toronto, Canada
Moderator: Dr. Jason Grebely, University of New South Wales, Sydney, Australia

15h40 - 15h50  Update on Restriction of Reimbursement of Treatments/Drugs in Canada
Alison Marshall, University of New South Wales, Sydney, Australia

15h50 - 16h30  Panel and Audience Discussion – Table ronde et discussion avec l’audience
From Research to Action: How to Translate Research into Policy Change
Moderator: Dr. Mel Krajden, University of British Columbia, Vancouver, Canada
Panelists: Glenn Betteridge, CTAC, Dr. Howard Njoo, PHAC, Dr. Dan Werb, University of San Diego

16h30 - 16h45  Closing Remarks – Mot de la fin
Dr. Marina Klein, McGill University, Montréal, Canada

16h45 - 18h30  Cocktail and Poster Session – Cocktail et présentation des affiches: Saint-Laurent and Gatineau, Convention Floor

Organizing Committee - Comité organisateur

Marina Klein, McGill University, Chair  Mel Krajden, University of British Columbia
Selena M. Sagan, McGill University, Co-Chair  Gerry Mugford, Memorial University
Julie Bruneau, Université de Montréal  Rodney Russell, Memorial University
Frank Bialystok, University of Toronto  Sahar Saeed, McGill University (Trainee Representative)
Curtis Cooper, University of Ottawa  Luis Schang, University of Alberta
Maryam Ehteshami, Emory University  Naglaa Shoukry, Université de Montréal
Jordan Feld, University Health Network  Hugo Soudyns, Université de Montréal
Jason Grebely, University of New South Wales  Nicholas van Buuren, Stanford University
Matthias Götze, University of Alberta  Joyce Wilson, University of Saskatchewan

For more information please contact Norma Choucha at ncrtp.hepc@gmail.com
Pour plus d’information, veuillez communiquer avec Norma Choucha @ ncrtp.hepc@gmail.com
THE SWEET SUCCESS of SIXTEEN YEARS

07:00-07:45  REGISTRATION / BUFFET BREAKFAST

07:45-08:00  WELCOME
Carolyn Klassen - President, CAHN

Session #1  
Moderator: Lori Lee Walston

08:00-09:00  The Next Generation of HCV Treatments
Dr. David Wong, MD, FRCPC

09:00-09:30  Management of HCV/HIV Co infection in the IFN - free era.
Dr. Marina Klein, MD, Msc, FRCP(C)

09:30-10:00  Case Studies
1. HIV/HCV Co-infection  TBA
2. First Nation Communities
Diane Perreault RN & Denise Thomas RN

10:00-10:20  NUTRITION BREAK

Session #2  
Moderator: Sheryl Wolfstadt

10:20-10:50  Emerging drug patterns and HCV transmission
Dr. Julie Bruneau, MD

10:50-11:30  Women’s Diagnosis Experience
Donna Zukowski, MScN
Sandi Mitchell, MScN, PhD(c)

11:30-12:00  The Transplant Journey
Cheryl Dale, RN (EC), MScN, NP

12:00-13:15  LUNCH

Session #3  
Moderator: Diane Perreault

13:15-14:00  Dietary Requirements for HCV Pts – Cirrhotic and Decompensate
Colleen McGuire, MA RD

14:00-14:45  HCV in Quebec from a NP Perspective
Isabelle Tétu, NP

14:45-15:10  NUTRITION BREAK

15:10-16:00  Hepatology Nursing: Looking Back Looking Forward
Original CAHN Members Panel

Wrap- up  
Sandi Mitchell and Lisa Abraham
### CAG Presidents

<table>
<thead>
<tr>
<th>Year</th>
<th>Name</th>
<th>Year</th>
<th>Name</th>
<th>Year</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>1964-1965</td>
<td>Eric M Nanson (University of Saskatchewan)</td>
<td>1979-1980</td>
<td>Florent Thibert (Université de Montréal)</td>
<td>1994-1996</td>
<td>D Grant Gall (University of Calgary)</td>
</tr>
<tr>
<td>1966-1967</td>
<td>KJR Wightman (University of Toronto)</td>
<td>1981-1982</td>
<td>Gordon G Forstner (University of Toronto)</td>
<td>1997-1998</td>
<td>Gary A Levy (University of Toronto)</td>
</tr>
<tr>
<td>1971-1972</td>
<td>John M Finlay (University of Toronto)</td>
<td>1986-1987</td>
<td>C Noel Williams (Dalhousie University)</td>
<td>2006-2008</td>
<td>William Paterson (Queen's University)</td>
</tr>
<tr>
<td>1973-1974</td>
<td>Joseph J Sidorov (Dalhousie University)</td>
<td>1988-1989</td>
<td>Aubrey Groll (Queen's University)</td>
<td>2010-2012</td>
<td>David Morgan (McMaster University)</td>
</tr>
<tr>
<td>1974-1975</td>
<td>Jacques O Gagnon (Université de Montréal)</td>
<td>1989-1990</td>
<td>Iain G Cleator (University of British Columbia)</td>
<td>2012-2014</td>
<td>Daniel Sadowski (University of Alberta)</td>
</tr>
</tbody>
</table>

### The Richard D McKenna Lecturers

<table>
<thead>
<tr>
<th>Year</th>
<th>Name</th>
<th>Year</th>
<th>Name</th>
<th>Year</th>
<th>Name</th>
</tr>
</thead>
</table>

### The Richard D McKenna Memorial Lecturers

<table>
<thead>
<tr>
<th>Year</th>
<th>Name</th>
<th>Year</th>
<th>Name</th>
<th>Year</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>1978</td>
<td>Howard M Spiro</td>
<td>1992</td>
<td>Francisco Villardell</td>
<td>2006</td>
<td>Peter B Cotton</td>
</tr>
<tr>
<td>1983</td>
<td>Henri Bismuth</td>
<td>1997</td>
<td>Leslie Tumberge</td>
<td>2011</td>
<td>Loren Laine</td>
</tr>
<tr>
<td>1985</td>
<td>John M Dietschy</td>
<td>1999</td>
<td>Eugene B Chang</td>
<td>2013</td>
<td>Fergus Shanahan</td>
</tr>
<tr>
<td>1987</td>
<td>R Hermon Dowling</td>
<td>2001</td>
<td>Juan R Malagelada</td>
<td>2015</td>
<td>Don Powell</td>
</tr>
<tr>
<td>1988</td>
<td>Leslie S Valberg</td>
<td>2002</td>
<td>Joseph Sung</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1989</td>
<td>Claude C Roy</td>
<td>2003</td>
<td>Kim Barrett</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### CAG Distinguished Service Award Winners

<table>
<thead>
<tr>
<th>Year</th>
<th>Name</th>
<th>Year</th>
<th>Name</th>
<th>Year</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(posthumously)</td>
<td>1995</td>
<td>JAL Gilbert</td>
<td>2007</td>
<td>J Joseph Connin</td>
</tr>
<tr>
<td>1993</td>
<td>Doug Kinnear</td>
<td>1998</td>
<td>Kursheed N Jeejeebhoy</td>
<td>2010</td>
<td>Grant Gail (posthumously)</td>
</tr>
<tr>
<td>1994</td>
<td>Leslie Valberg</td>
<td>2002</td>
<td>Eldon Shaffer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1995</td>
<td>Richard R Gillies</td>
<td>2004</td>
<td>Nicholas Diamant</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### CAG Education Excellence Award Lecturers

<table>
<thead>
<tr>
<th>Year</th>
<th>Name</th>
<th>Year</th>
<th>Name</th>
<th>Year</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>2003</td>
<td>Claude Roy</td>
<td>2007</td>
<td>Alan BR Thomson</td>
<td>2011</td>
<td>Eldon Shaffer</td>
</tr>
<tr>
<td>2004</td>
<td>Ivan T. Beck</td>
<td>2008</td>
<td>Desmond Leddin</td>
<td>2012</td>
<td>Connie Switzer</td>
</tr>
<tr>
<td>2005</td>
<td>Khursheed Jeejeebhoy</td>
<td>2009</td>
<td>David Armstrong</td>
<td>2013</td>
<td>Sylvain Coderre</td>
</tr>
<tr>
<td>2006</td>
<td>Lloyd Sutherland</td>
<td>2010</td>
<td>Norman Marcon</td>
<td>2014</td>
<td>Nicola Jones</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2015</td>
<td>Sander van Zanten</td>
</tr>
</tbody>
</table>

### Kopelman Award Lecturers

<table>
<thead>
<tr>
<th>Year</th>
<th>Name</th>
<th>Year</th>
<th>Name</th>
<th>Year</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>2005</td>
<td>Dana Philpott</td>
<td>2009</td>
<td>Philip Sherman</td>
<td>2014</td>
<td>Jeffrey Hyams</td>
</tr>
</tbody>
</table>

### CAG Research Excellence Award Lecturers

<table>
<thead>
<tr>
<th>Year</th>
<th>Name</th>
<th>Year</th>
<th>Name</th>
<th>Year</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>1993</td>
<td>Alan BR Thomson</td>
<td>2001</td>
<td>Mary Perdue</td>
<td>2009</td>
<td>Derek M Kay</td>
</tr>
<tr>
<td>1994</td>
<td>Claude C Roy</td>
<td>2002</td>
<td>Jan Huizinga</td>
<td>2010</td>
<td>Herbert Gaisano</td>
</tr>
<tr>
<td>1998</td>
<td>John L. Wallace</td>
<td>2006</td>
<td>Keith Sharkey</td>
<td>2014</td>
<td>Wallace MacNaughton</td>
</tr>
<tr>
<td>1999</td>
<td>Philip M Sherman</td>
<td>2007</td>
<td>André Buret</td>
<td>2015</td>
<td>Paul Beck</td>
</tr>
<tr>
<td>2000</td>
<td>William G Paterson</td>
<td>2008</td>
<td>Stephen Vanner</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### CAG Visiting Research Professor Award Winners

<table>
<thead>
<tr>
<th>Year</th>
<th>Name</th>
<th>Year</th>
<th>Name</th>
<th>Year</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>1983</td>
<td>Claude C Roy</td>
<td>1997</td>
<td>D Grant Gall</td>
<td>2008</td>
<td>Philip Sherman</td>
</tr>
<tr>
<td>1984</td>
<td>Eldon A Shaffer</td>
<td>1998</td>
<td>Mary Perdue</td>
<td>2009</td>
<td>Alan NG Barkun</td>
</tr>
<tr>
<td>1985</td>
<td>J Richard Hamilton</td>
<td>1999</td>
<td>Lloyd Sutherland</td>
<td>2010</td>
<td>Charles Bernstein</td>
</tr>
<tr>
<td>1987</td>
<td>Richard H Hunt</td>
<td>2000</td>
<td>Ernest Seidman</td>
<td>2011</td>
<td>Derek M Kay</td>
</tr>
<tr>
<td>1993</td>
<td>Stephen M Collins</td>
<td>2005</td>
<td>Brian Feagan</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1994</td>
<td>Gary A Levy</td>
<td>2006</td>
<td>Gordon R Greenberg</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### CAG Visiting Clinical Professor Award Winners

<table>
<thead>
<tr>
<th>Year</th>
<th>Name</th>
<th>Year</th>
<th>Name</th>
<th>Year</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td>David Armstrong</td>
<td>2013</td>
<td>Rob Enns</td>
<td>2014</td>
<td>Chris Andrews</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2015</td>
<td>Anne Griffiths</td>
</tr>
</tbody>
</table>
### CASL Presidents

<table>
<thead>
<tr>
<th>Year</th>
<th>President</th>
<th>University/Institution</th>
<th>Year</th>
<th>President</th>
<th>University/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>1983-1987</td>
<td>Eldon A Shaffer</td>
<td>(University of Calgary)</td>
<td>2006-2008</td>
<td>Marc Deschénes</td>
<td>(McGill University)</td>
</tr>
<tr>
<td>1987-1988</td>
<td>W Wayne Laut</td>
<td>(University of Manitoba)</td>
<td>2008-2010</td>
<td>Eric Yoshida</td>
<td>(University of British Columbia)</td>
</tr>
<tr>
<td>1988-1989</td>
<td>Jerome B Simon</td>
<td>(Queen’s University)</td>
<td>2010-2012</td>
<td>Winnie Wong</td>
<td>(University of Alberta)</td>
</tr>
<tr>
<td>1989-1990</td>
<td>Lloyd Sutherland</td>
<td>(University of Calgary)</td>
<td>2012-2014</td>
<td>Kevork Petekian</td>
<td>(Dalhousie University)</td>
</tr>
<tr>
<td>1990-1991</td>
<td>Laurence M Blendis</td>
<td>(University of Calgary)</td>
<td>2014-2016</td>
<td>Eberhard Renner</td>
<td>(University of Toronto)</td>
</tr>
<tr>
<td>1991-1992</td>
<td>Gerald Y Minuk</td>
<td>(University of Manitoba)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1992-1994</td>
<td>Pierre-Michel Huet</td>
<td>(University of Toronto)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1993-1994</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### CLF/CASL Gold Medalists

<table>
<thead>
<tr>
<th>Year</th>
<th>Recipient</th>
<th>Year</th>
<th>Recipient</th>
<th>Year</th>
<th>Recipient</th>
</tr>
</thead>
<tbody>
<tr>
<td>1984</td>
<td>Robert Purcell</td>
<td>1995</td>
<td>Diane W Cox</td>
<td>2006</td>
<td>Harvey Alter</td>
</tr>
<tr>
<td>1986</td>
<td>Sheila Sherlock</td>
<td>1997</td>
<td>Lawrie W Powell</td>
<td>2008</td>
<td>Eve Roberts</td>
</tr>
<tr>
<td>1988</td>
<td>Carl A Goresky</td>
<td>1999</td>
<td>Juan Rodes</td>
<td>2010</td>
<td>Paul Adams</td>
</tr>
<tr>
<td>1990</td>
<td>Baruch S Blumberg</td>
<td>2001</td>
<td>Jay Hoofnagle</td>
<td>2012</td>
<td>Jaime Bosch</td>
</tr>
<tr>
<td>1992</td>
<td>Roger Williams</td>
<td>2003</td>
<td>Roger Butterworth</td>
<td>2014</td>
<td>Jordi Bruix</td>
</tr>
</tbody>
</table>

### CASL/SASS Kortsaak Lectureship

<table>
<thead>
<tr>
<th>Year</th>
<th>Recipient</th>
<th>Year</th>
<th>Recipient</th>
<th>Year</th>
<th>Recipient</th>
</tr>
</thead>
<tbody>
<tr>
<td>1992</td>
<td>Claude C Roy</td>
<td>2000</td>
<td>Frederick Suchy</td>
<td>2008</td>
<td>Milton Finegold</td>
</tr>
<tr>
<td>1994</td>
<td>Daniel Alagille</td>
<td>2002</td>
<td>Jean-Bernard Otte</td>
<td>2010</td>
<td>Peter F Whittington</td>
</tr>
<tr>
<td>1996</td>
<td>Alex P Mowat</td>
<td>2004</td>
<td>Andrée Rasquin</td>
<td>2013</td>
<td>Giorgina Melli-Vergani</td>
</tr>
<tr>
<td></td>
<td>(posthumously)</td>
<td></td>
<td></td>
<td>2014</td>
<td>Mei Hwei Chang</td>
</tr>
<tr>
<td>Year</td>
<td>Name</td>
<td>Year</td>
<td>Name</td>
<td>Year</td>
<td>Name</td>
</tr>
<tr>
<td>------</td>
<td>-----------------------</td>
<td>------</td>
<td>-----------------------</td>
<td>------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>2008</td>
<td>Gilles Pomier-Layrargues</td>
<td>2010</td>
<td>Eldon Shaffer</td>
<td>2012</td>
<td>Vince Bain</td>
</tr>
<tr>
<td>2009</td>
<td>Morris Sherman</td>
<td>2011</td>
<td>Cameron Ghent</td>
<td>2014</td>
<td>Gerald Minuk</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2015</td>
<td>Samuel Lee</td>
</tr>
</tbody>
</table>
### 2016 CAG RESEARCH PROGRAM
IN COLLABORATION WITH THE CIHR AND OUR VALUED RESEARCH PARTNERS

<table>
<thead>
<tr>
<th>Program</th>
<th>Sponsor</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>CCC-CIHR-CAG New Investigator Award (1)</td>
<td>AbbVie</td>
<td>5 years</td>
</tr>
<tr>
<td>CCC-CIHR-CAG IBD Fellowships (3)</td>
<td>Allergan</td>
<td>2 years</td>
</tr>
<tr>
<td>CAG-CIHR Fellowships (2)</td>
<td>Takeda</td>
<td>2 years</td>
</tr>
<tr>
<td>AbbVie-CIHR-CAG IBD Fellowship (1)</td>
<td>Takeda</td>
<td>2 years</td>
</tr>
<tr>
<td>Allergan-CIHR-CAG Moptility Fellowship (1)</td>
<td>Pentax</td>
<td>2 years</td>
</tr>
<tr>
<td>Takeda-CIHR-CAG Fellowship (1)</td>
<td>Shire</td>
<td>2 years</td>
</tr>
<tr>
<td>Pentax-CIHR-CAG Endoscopy Fellowship (1)</td>
<td>Ferring</td>
<td>2 years</td>
</tr>
<tr>
<td>Shire-CAG Research Resident Awards (2)</td>
<td>Allergan</td>
<td>1 year</td>
</tr>
<tr>
<td>Ferring-CAG Research Resident Awards (2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Allergan-CAG Research Resident Award (1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CAG Summer Studentships (12)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CCC Summer Studentships (6)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CDHF-CAG Ivan Beck Memorial Summer Studentship (1)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The CAG wishes to express its sincere appreciation to the above sponsors for their support of these Research Programs.